Impact of Cost Sharing Levels on Adherence to Controller Drugs and Consequent Outcomes among Asthma Patients by Vaidya, Varun
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
5-2009
Impact of Cost Sharing Levels on Adherence to
Controller Drugs and Consequent Outcomes
among Asthma Patients
Varun Vaidya
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Health and Medical Administration Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Vaidya, Varun , "Impact of Cost Sharing Levels on Adherence to Controller Drugs and Consequent Outcomes among Asthma
Patients" (2009). Theses and Dissertations (ETD). Paper 277. http://dx.doi.org/10.21007/etd.cghs.2009.0332.
Impact of Cost Sharing Levels on Adherence to Controller Drugs and
Consequent Outcomes among Asthma Patients
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Health Outcomes and Policy Research
Research Advisor
Song Hee Hong, Ph.D.
Committee
Raoul Arreola, Ph.D. Dick Gourley, Pharm.D. Jim Wan, Ph.D. Shelly White-Means, Ph.D.
DOI
10.21007/etd.cghs.2009.0332
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/277
  
IMPACT OF COST SHARING LEVELS ON ADHERENCE TO 
CONTROLLER DRUGS AND CONSEQUENT OUTCOMES AMONG 
ASTHMA PATIENTS 
 
 
 
 
 
 
 
 
A Dissertation Presented for 
The Graduate Studies Council 
The University of Tennessee 
Health Science Center 
 
 
       
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy 
From The University of Tennessee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
Varun Vaidya 
May 2009
ii 
Copyright © 2009 by Varun Vaidya 
All rights reserved 
  
iii 
Dedication 
 
 
This dissertation is dedicated to my wife Renuka  
and my parents,  
Dr. Anil Vaidya  and Mrs. Anjali Vaidya. 
  
iv 
Acknowledgements 
 
 
I would like to thank my major professor, Dr. Song Hee Hong for his support and 
help throughout this dissertation process. 
 
I would also like to thank my dissertations committee members; Dr. Raoul 
Arreola, Dr. Dick Gourley, Dr. Jim Wan and Dr. Shelley White-Means for providing me 
excellent feedback and also for their continuous encouragement. Without them this 
dissertation could not have been possible. 
 
I would like to thank Thomason Reuters for providing the MarketScan 
administrative claims database. 
 
Finally I would like to thank all my friends and colleagues at UT for always being 
there for me. 
  
v 
Abstract 
 
 
Prescription drug cost sharing is an effective tool to reduce the excessive drug 
consumption. However, many times it could have a negative impact on the drug 
utilization especially in case of chronic conditions. Chronic conditions such as asthma 
require appropriate utilization of controller medication to keep the inflammation and 
symptoms under control. Literature on asthma drug utilization has consistently reported 
underuse of controller drugs among asthma patients. The present study attempted to 
investigate the impact of prescription drug cost sharing levels on the controller adherence 
among the privately insured asthma population with moderate persistent asthma. The 
study also analyzed the relationship between adherence and asthma related health 
services utilization outcomes. 
 
A retrospective analysis using the MarketScan administrative claims database was 
conducted for the years 2000 and 2001. Asthma patients that were stepped up to dual 
controller therapy in the study period and had no diagnosis for COPD or other respiratory 
conditions were included in the study. Study participants were also required to be in the 
age range of 5-65 and continuously enrolled in the health plan for the entire study period. 
Multivariate regression analysis using SAS 9.1 was performed to analyze the relationship 
between cost sharing levels and controller adherence. Linear probabilistic models were 
built to analyze the relationship between adherence and asthma related health services 
utilization. 
 
A total of 1447 patients met the study criteria. The overall association between 
cost sharing and adherence was significantly negative. The drop in adherence to Inhaled 
Corticosteroids (ICS) with respect to cost sharing was greater after the patients were 
stepped to the dual controller therapy.  Comparison of subgroups that used ICS+ LABA 
and ICS + LTRA revealed that the subjects ICS+LTRA subgroup are slightly more 
sensitive to the out of pocket costs. The analysis of adherence and health services 
utilization showed mixed results with reduction in ER visits but no association of hospital 
stay and SAB use.   
 
Cost sharing levels had a negative impact on utilization of controller drugs.  In 
terms of ICS adherence pre and post index periods, it can be concluded that the increased 
cost burden affected significantly even though the need to be adherent was increased. 
Based on the sub group analysis in the post-index period between the two add-on options, 
ICS + LTRA subgroup was more sensitive to the price changes. Adherence to controller 
regimen had a negative impact on ER visits however the data did not provide evidence in 
case of hospitalizations and SAB use.  
vi 
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Chapter I: Introduction 
 
 
1.1 Overview 
 
The concept of cost sharing in healthcare has been around for years. Work 
published by health economist Kenneth Arrow demonstrated the phenomenon of moral 
hazard among those with health insurance,
1
 which in turn stimulated a need to contain the 
moral hazard. Moral hazard is defined as the change in behavior when people are 
insulated from risk.
2
 It happens when an individual does not carry the responsibility of 
their actions, has a tendency to act less carefully than he/she otherwise would. In a 
response to counter the moral hazard, insurance companies started using several cost 
sharing techniques such as annual deductibles and co-payments to control the overall 
healthcare expenditures. The success of cost sharing techniques in controlling the moral 
hazard is well documented by previous studies.
3-5
 However, while the cost sharing 
strategy is observed as an excellent tool to counter the moral hazard and unnecessary 
drug utilization, it has also been documented that the higher cost sharing levels may lead 
to under use of heath care.
6
 Hence to maintain an optimum balance between cost sharing 
and appropriate health care consumption, it is important to study the effect of cost sharing 
on patient adherence to the treatment.  
 
Even though prescription drugs are part of health care services, in a typical health 
insurance coverage policy they are separated from other health services and form a 
supplementary addition to a health coverage policy. However, as the prices for 
prescription drugs started rising, insurance companies have introduced cost sharing 
policies in the supplementary drug policies as well. The main purpose of cost sharing 
again was to discourage patients from consuming unnecessary care. On the other hand if 
the patients have to pay too much out of pocket cost they may be discouraged from 
utilizing necessary care. Therefore achieving the correct balance where patients are 
encouraged to use needed care but at the same time are discouraged to use unneeded care 
is critical. This brings us to an important issue where we need to determine if cost sharing 
levels imposed in the drug plans are adversely affecting utilization of necessary drugs 
especially in cases of chronic conditions where poor adherence may lead to worse 
outcomes.  
 
In this study, the investigator sought to determine the impact of cost sharing on 
adherence to asthma controller drugs among asthma patients from age five and above. 
The focus was on the patients with asthma severity at a moderate persistent level which is 
characterized by use of more than one controller medication. In case of moderate 
persistent asthma, the patients need more medical attention as their asthma is not 
controlled by one controller medication alone. Poor adherence to the controller 
2 
medication has more severe implications in case of these asthma patients. Therefore 
compared to the asthma patients with mild asthma these patients are in greater need of 
being adherent to the prescribed regimen for asthma treatment.     
 
 
1.2 Background 
 
Asthma is a chronic respiratory condition and if not managed effectively it may 
result in hospitalizations, emergency room visits, and reduced quality of life.
7
 Besides 
avoiding the things that trigger an asthma attack, the most effective treatment for asthma 
is use of medications.
8  
There are mainly two types of medications available for asthma 
treatment, short acting relievers and long acting controllers. The current National Heart, 
Lung, and Blood Institute (NHLBI) guidelines
8
 for the treatment of persistent asthma 
advocate use of long-term control medications (to be taken daily on a long-term basis) to 
achieve and maintain adequate control. For asthma patients suffering from daily 
symptoms and requiring use of Short Acting Bronchodilators (SAB) on an everyday basis 
along with exacerbations affecting activity greater than two times per week, guidelines 
recommend use of dual controller therapy.
9
 Dual controller therapy is a combination of 
Inhaled Corticosteroids (ICS) along with another controller drug such as Long-acting 
inhaled 2-agonist (LABA) or Leukotrine Receptor Antagonist (LTRA). 
 
 
1.2.1 Poor adherence to controller drugs 
 
Despite the recommendations from national asthma guidelines, the controller drug 
underutilization and overuse of the quick relief medications still persists.
10-12
 The 
Epidemiology and Natural History of Asthma Outcomes and Treatment Regimens 
(TENOR) study reported that the controller drug utilization is less than optimum among 
many asthma patients who are at high risk of morbidity and mortality.
11
 The asthma 
medication treatment emphasis is shifting towards more use of the controller drugs that 
are effective in preventing asthma exacerbations than the relievers that play no role in 
controlling the asthma itself. Poor adherence to the controller drugs is also considered a 
major contributor towards poor control and morbidity associated with asthma. If asthma 
is not controlled adequately then it can affect the severity levels of the disease resulting in 
more severe asthma condition.  
 
For asthma patients having moderate persistent or higher severity, NHLBI 
guidelines
9
 emphasize even greater focus on use of controller drugs. Patients are 
recommended to initiate a step up therapy consisting of two different controller drugs. 
However, studies have reported lower rate of adherence even among these patients that 
3 
needs more attention. Stern et al reported an average MPR (Medication Possession Ratio) 
of 0.36 among the asthma population taking more than one controller medication.
12
 
 
Considering that the value for MPR ranges from 0 to 1, 0.36 indicates a very low 
adherence. Unfortunately there is no cure for asthma and the only means to treat asthma 
besides avoiding the substances that trigger asthma attacks is to use medications. Poor 
adherence to controller medications even among asthma patients that are in more need to 
control their conditions, highlights the need to investigate factors behind the low 
adherence and possible solutions to improve the adherence.       
 
 
1.2.2 Relationship between out of pocket cost and adherence  
 
As mentioned earlier out of pocket cost has an inverse relationship with adherence 
to the medications across a wide range of chronic conditions. Several studies
6,13-15
 have 
documented significant rates of medication underuse as a result of the burden of out of 
pocket costs in the United States. In the case of chronic conditions such as asthma, 
medication adherence is essential to control the disease. However, if out of pocket costs 
are unaffordable to the patients, then it is likely that they will skip the medication. 
Moreover, majority of the controller drugs (such as widely used ICS) do not produce any 
symptomatic relief making them more vulnerable to poor adherence rates. A study done 
by Byer et al
16
 using Leventhal‟s Self Regulatory Model (SRM) as a theoretical 
framework found that the symptoms associated with the illness play a key role in 
adherence to then medication among asthma patients. Medications such as asthma 
controllers have to be taken for a very long time without being able to experience 
immediate symptomatic relief and therefore higher costs associated with such 
medications can discourage the patients from utilizing the drugs properly.  
 
As mentioned before, lower adherence to controller drugs can lead to worsening 
the asthma symptoms which ultimately can result in a stepped up therapy with dual 
controller medications.
17
 According to national guidelines patients are stepped up from 
one controller medication to two medications when asthma is not controlled enough by 
one controller alone.
9
 To achieve better control over the condition, patients need more 
than one controller drugs. Severity indicators such as inflammation levels and lung 
function are worse among such patients and therefore they are required to be more 
adherent to the treatment regimen than the patients having their asthma severity at mild 
level.  
 
Once the patients are stepped up to the dual controller therapy they have to pay 
for two controller drugs making the overall treatment less affordable and more 
4 
burdensome. Compared to the reliever drugs, controller drugs are more expensive and 
when searched for the various drug plans offered in Tennessee were found to be placed in 
the second or third tier of the pharmacy benefit plan. According to drugstore.com (an 
online retailer of prescription drugs), the cost of Azmacort (asthma controller drug) 
inhaler was found to be $131.24 whereas Alupent (Short Acting Bronchodilator) - 
0.65mg/act Aerosol 14gm Inhaler was found to be for $37.87.  
 
 
1.3 Conceptual Framework 
 
As improved outcomes are expected through appropriate adherence to them, first 
it is necessary to establish a relationship between the health insurance status and asthma 
drug utilization, before analyzing the economical and health outcomes. However the 
individual healthcare utilization cannot be explained as a function of coinsurance level 
alone. It is characterized by a person‟s individual and social determinants. In order to 
measure the isolated effects of health insurance status on the drug utilization, it is 
necessary to identify and control for all the individual and social characteristics that are 
likely to influence one‟s health care utilization. To control the factors influencing one‟s 
prescription drug utilization, the conceptual framework of this study incorporated the 
health utilization model developed by R.M Anderson
15 
 
This model has been cited by several studies
18-20
 focusing on health services 
utilization among asthma patients. Initially this model was developed to focus on „family‟ 
as the unit of analysis. Later on it was modified to shift the focus to the „individual‟ as the 
unit of analysis to address the health services utilization more appropriately.
21
 This model 
captures health services utilization behavior as a function of their 1) predisposition to use; 
2) enabling resources to use; and 3) need to use the health services.   
 
 
1.3.1 Predisposing characteristics  
 
Every individual has a different propensity to use health care resources.
21
  
Existence of different propensities is a result of the diversity in characteristics of every 
individual.  Such characteristics are broadly categorized into demographic, social 
structural and attitudinal-belief variables under the predisposing factors to use the health 
care services. Demographics such as age and sex are examples of demographic variables 
that are closely related to health of an individual. The social structure variables refer to 
the status of the individual in his society. Depending upon these characteristics use of 
health care services varies among different patient populations. Although predisposing 
variables are not directly associated with the patient‟s healthcare utilization patterns, they 
5 
create differences in inclinations towards use of health care services. As a result, the 
different healthcare utilization patterns are observed with different predisposing 
characteristics. For example, people in different age groups have different types of 
illnesses and severities and therefore are likely to have different healthcare use patterns. 
In case of asthma predisposing factor such as age is important because the evidence 
indicates that aging has an adverse effect on lung elastin fibers which has been correlated 
to the severity of the disease.
22
  
 
 
1.3.2 Enabling resources  
 
Being predisposed to utilization alone may not result in actual utilization of the 
health services. Along with predisposition to use, adequate resources are required to be 
available to translate the predisposition into actual use. There are two major categories of 
enabling resources, personal/ family and community. Family/personal income is an 
example of variable in personal/family category affecting individual utilization of health 
services. Variables such as, availability of health care facilities and access to them fall 
under the community category of enabling resources. Other community variables such as 
rural or urban nature of the community also influence use of health services because they 
sometimes are associated with the way how the medicine should be practices. Enabling 
resources play a key role by providing necessary means to obtain the health care services 
by the patients.  
 
 
1.3.3 Need 
 
Other than the predisposition to use and availability of enabling resources, 
presence of an illness and degree of it is also important in predicting health services use. 
It is important for an individual or a family to perceive the illness or probability of its 
occurrence to seek any kind of health care services. Being predisposed and availability of 
necessary means are not sufficient to use healthcare services if there is no need for it 
perceived by the individual or the family. Need characteristics explain the behavior of 
those patients who are predisposed to the health care use and also have means to obtain it 
but are still not consuming it. Illness level represents the most immediate cause to use any 
health services. Examples of perceived illness include self reported general state of health 
such as excellent, good, poor etc.   
 
The final conceptual framework for this study (Figure 1) was created by 
extending the Anderson‟s health utilization model further to include the asthma related 
healthcare resources utilization outcomes. 
6 
 
 
 
Figure 1 Conceptual framework based on Anderson‟s healthcare utilization model  
 
Source: Modified with permission Andersen RM. Revisiting the behavioral model and 
access to medical care: does it matter? J Health Soc Behav 1995 March;36(1):1-10.
18
  
Legend: ER = Emergency Room.  
SAB = Short Acting Bronchodilators.  
  
7 
Once the link between cost sharing and medication utilization is established it is 
important to analyze effects of adherence levels on healthcare resources utilization 
outcomes to fully understand the impact of cost related poor adherence. Cost related poor 
adherence has been documented to be associated with poor health outcomes in case of 
chronic conditions.
23
 Extending the Anderson‟s model to include healthcare services 
utilization outcomes, helped to understand if patients who are struggling to be adherent to 
the controller regimen are suffering from poor healthcare resources utilization outcomes 
as well. Healthcare services utilization outcomes associated with asthma such as ER visit, 
hospitalization and use of SAB were included. This conceptual framework helped us to 
determine the variables to be measured and also the statistical relationships required to be 
studied.  
 
 
1.4 Objectives and Specific Aims 
 
 
1.4.1 Objectives 
 
The main objectives of this study were to examine the impact of cost sharing 
among asthma population suffering from moderate persistent asthma (age group 4-65) on 
adherence to asthma controller medications and also to analyze patient level outcomes 
such as ER visits, hospitalization and use of SAB.  The study had the following specific 
aims:  
 
 
1.4.2 Specific aims and hypotheses 
 
1. To determine the distribution of asthmatic population diagnosed with 
moderate persistent asthma (stepped up from Inhaled corticosteroids alone to 
Inhaled Corticosteroids + Long-acting inhaled 2-agonist (ICS+LABA) and 
Inhaled Corticosteroids + Leukotrine Receptor Antagonist (ICS + LTRA)) 
 
2. To quantify  the change in Medication Possession Ratio (adherence measure) 
of controller medication combination (ICS+LABA/LTRA) with respect to 
increase in cost sharing level after controlling for other covariates. 
Hypothesis: As the increased cost sharing levels are known to have inverse 
relationship with the utilization of health care services, it is hypothesized that 
the MPR for the asthma patients will go down as the cost sharing levels go up. 
The null and alternative hypotheses are, 
H0:  MPR does not change with change in cost sharing levels  
8 
H1:  MPR changes with change in cost sharing levels  
 
2a.  To compare changes in Medication Possession Ratio (adherence 
measure) with respect to increase in cost sharing level between 
patients stepped up with ICS+LABA and patients stepped up with 
ICS+LTRA combination 
Hypothesis: As the LABA and LTRA have different mechanism of 
actions it is hypothesized that adherence levels will be with respect to 
the cost sharing levels will be significantly different. The null and 
alternative hypotheses are, 
H0:  There is no change in MPR with respect to cost sharing levels 
among ICS+LABA and ICS+LTRA users. 
H1:  The MPR with respect to cost sharing levels changes among 
ICS+LABA and ICS+LTRA users. 
 
2b.  To analyze change in medication possession ratio with respect to   
increase in cost sharing levels of ICS only before and after the 
patients were stepped up to the dual controller therapy. 
Hypothesis: As the increased cost sharing levels are known to have 
inverse relationship with the utilization of health care services, it is 
hypothesized that the MPR for the asthma patients will go down as 
the cost sharing levels go up. The null and alternative hypotheses are, 
H0:  There is no change in ICS MPR with respect to cost sharing 
levels before and after getting steeped up to dual controller therapy. 
H1:  The ICS MPR with respect to cost sharing levels changes before 
and after getting stepped up to dual controller therapy. 
 
3. To examine the association between adherence to asthma controller therapy 
and asthma related health services utilization (SAB utilization, ER visits, 
Hospitalization) among the moderate persistent asthma patients.  
Hypothesis: The controller therapy has been reported to be effective for the 
asthma patients in controlling the conditions and therefore it is hypothesized 
that the adherence levels will result in decreasing the asthma related health 
services utilization such as SAB use, ER visits, Hospitalization. The null and 
alternative hypotheses are, 
H0:  Adherence to controller drugs has no impact on asthma related health 
services utilization. 
H1:  Adherence to controller drugs has a negative impact on asthma related 
health services utilization. 
 
9 
1.5 Significance 
 
The prevalence of asthma along with the severity and frequency of exacerbations 
appears to be increasing worldwide.
24
 In addition the lower rates of controller adherence 
are contributing to worsening the situation. Despite the recommendations from guidelines 
to use more than one controller drug, the studies have reported lower levels of controller 
adherence even among asthma patients having moderate persistent asthma. So far the 
factors reported in the literature to be associated with lower adherence to controller 
medications are lack of medication efficacy (real or perceived), taste of medication, 
multiple dosing intervals, long stressful demanding regimens and incorrect prescription 
given by clinicians.
12
  
 
At the same time to control the increase in prescription drug spending many plans 
are increasing the levels of copayment across all tiers leading to an increased cost burden 
on patients.
25
 This increase in copayment level brings up two important issues needed to 
be addressed: 1) Does the increase in cost sharing level affect the utilization of 
appropriate prescription drugs; and 2) To what degree the health outcomes associated 
with the utilization are affected. There is a significant body of research showing the 
association of higher cost sharing and lower adherence levels, but impact of cost sharing 
on adherence in case of asthma patients has not been explored thoroughly with only a few 
studies available. As explained before, among asthma patients poor adherence levels of 
controller drugs are reported and since the role played by increasing cost sharing levels in 
the poor adherence has not been explored thoroughly it is important to produce more 
studies in this area. In this study the role played by cost sharing levels in adherence to 
controller drugs among the asthma patients having moderate persistent asthma was 
investigated. Investigating impact of cost sharing on adherence levels can help to 
understand the importance of cost burden as a barrier to access controller drugs. 
 
Additionally, the study also compared patient‟s adherence levels with respect to 
the cost sharing levels before they were diagnosed with moderate persistent asthma 
(stepped up to dual controller therapy). This helped to determine if there is any change in 
the sensitivity to the cost sharing levels after they were diagnosed with moderate 
persistent asthma. According to the guidelines patients are stepped up to the dual 
controller therapy when the asthma symptoms are not controlled adequately by using ICS 
alone. When the patients are stepped up to the dual controller therapy, the need to be 
adherent to the regimen is even greater. But on the other hand the cost burden is also 
increased because of the increased number of controller drugs. Therefore, studying the 
association of cost sharing with the adherence before and after the patients are stepped up 
provided a more comprehensive picture of the impact of cost sharing on adherence.  
10 
1.6 Study Limitations  
 
The analysis was carried out using medical and pharmacy claims data bases to 
examine the association of cost sharing and adherence to the controller regimen and 
relationship of adherence with the health outcomes. 
 
This study had limitations that are common to studies based on retrospective 
database analysis. The MarketScan databases did not have clinical information such as 
detailed asthma symptoms lung functions tests to assess the asthma severity more 
accurately. Although we controlled for the demographic factors such as age and gender, 
characteristics such as race and ethnicity were not available in the Market Scan databases 
that might have introduced some bias to the analysis. According to the literature of 
healthcare utilization, race and ethnicity are very important predictors of healthcare 
utilization. Cultural differences, multiple languages influence the access of health 
services. In general because of the cross-cultural difficulties and/or language  barriers 
people belonging to minority groups have been observed to have reduced utilization than 
whites.
26 Race and ethnicity are also believed to be major predictors of receiving several 
treatments and procedures.
27
 Regarding the chronic conditions such as asthma a study 
done by Agency for Healthcare Research and Quality (AHRQ)  revealed that only 7% of  
African Americans and only 2% of Hispanic children were prescribed routine asthma 
medications compared to the 21% of Caucasians.
27 However the data used for this study 
did not provide any information on this key predictor of health utilization. 
 
Regarding the demographic characteristics, the data did not allow information on 
income level or availability of secondary insurance that may also significantly influences 
health services utilization. It has been documented by that those who have higher income 
levels have better access and therefore higher rates of healthcare utilization compared to 
the poor population. Availability of secondary insurance may also influence utilization of 
health services as it provides additional financial assistance along with the primary 
insurance. 
 
The adherence was measured based on the pharmacy claims for the medication 
but the presence of pharmacy claim does not guarantee use of medication by the patient.  
Another aspect that is not considered in this analysis is technique in using inhalation 
devices. Number of asthma patients misuse their metered inhalers.
28
 Although by 
definition they are included in the more compliant groups they might be having poor 
health outcomes because of improper use of inhaler device. It is not possible to measure 
outcomes attributed to the improper inhaler use by using claims database. The study also 
had limitation inherent to the analysis of secondary data such as potential errors in data 
collection, coding errors and omission.  
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Further, this study also examined the outcomes such as Emergency Room (ER) 
visits, hospitalizations and the use of Short Acting Bronchodilators (SAB) to confirm 
how the better adherence is translated into better outcomes. Analyzing the cost related 
non-adherence and outcomes for the patients before getting stepped up helped us to 
understand if the higher cost sharing is associated with the outcomes that might result in 
to worsening the severity of asthma from mild to moderate. 
 
 
1.7 Terms and Definitions 
 
Administrative claims data: Administrative claims data are the electronic 
records of bills submitted by health care providers, hospitals, pharmacies, for office 
visits, hospital stays, or other encounters, or for sales of drugs or supplies. 
 
Asthma: A common disorder in which chronic inflammation of the bronchial 
tubes (bronchi) resulting in swelling and narrowing the airways. 
 
Benefit cap: Benefit caps limit the coverage for a specific amount and when the 
prescription drug expenditure reached that limit, patients do not receive any coverage and 
have to spend the entire cost out of pocket. 
 
Co-morbidity index: Comorbidity index captures the combined effect of all other 
diseases an individual patient might have other than the primary disease of interest. 
 
Controller medication: Controller medications are medication that are required 
to consume over a period of time to control airway inflammation and help prevent asthma 
exacerbations from occurring.  
 
Co-payment: A copayment, or copay, is a capped contribution defined in the 
policy and paid by an insured person each time a medical service is accessed. 
 
Demand curve: Demand curve is the graph illustrating the association between 
the price of a certain commodity, and the amount of it that consumers are willing and 
able to purchase at that given price. 
 
Direct costs: Costs related to the provision of medical care, including the 
screening, prevention, diagnosis, and treatment of diseases.
29
  
 
Emergency room services: Include visits to healthcare providers in an 
emergency room. 
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Formulary: Formulary is a list of prescription drugs approved for coverage under 
a specific health insurance plan. 
 
Indirect costs: Costs of illness related to loss in productivity by the individual 
who is ill and by family members who care for that individual.
29
  
 
Medicare Part D: Medicare Part D is a federal program to subsidize the costs of 
prescription drugs for Medicare beneficiaries in the United States. 
 
Medication adherence: Adherence to (or compliance with) a medication regimen 
is generally defined as, “the extent to which patients take medications as prescribed by 
their health care providers.”37 
 
Medication Possession Ratio (MPR): The Medication Possession Ratio (MPR) 
is a formula used to determine compliance that is measured from the first to the last 
prescription, with the denominator being the duration from index to the exhaustion of the 
last prescription and the numerator being the days supplied over that period from first to 
last prescription. 
 
Moral hazard: Moral hazard is defined as the change in behavior when people 
are insulated from risk.  
 
Out of pocket costs: The portion of the claim that the patient or enrollee is 
obligated to pay. 
 
Outpatient services: Visits to physicians and other medical providers seen in 
hospital outpatient departments.   
 
Pharmacoepidemiology: Pharmacoepidemiology is the study of the use of and 
the effects of drugs in large groups of people. 
 
Prevalence: the prevalence of a disease is defined as the total number of cases of 
the disease in the population at a given time, divided by the number of individuals in the 
population.  
 
Reliever medication: Asthma reliever is a drug that provides relief from asthma 
symptoms and is the most commonly used asthma medication.  
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Step-up therapy: When asthma symptoms are not controlled by the inhaled 
corticosteroids alone patients are recommended to take additional controller medications 
along with the minimum dose of ICS.  
 
 
1.8 Organization of the Dissertation 
 
This dissertation is organized into five chapters. Chapter I deals with the 
introduction and problem statement along with objectives and specific aims of this study. 
Chapter II provides a review of the literature covering literature on cost sharing and 
asthma controller treatment options. Chapter III presents the methods used in the 
research, while Chapter IV provides the results of the research.  Chapter V is a discussion 
of findings and possible future directions that the research may suggest.  
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Chapter II: Literature Review 
 
 
This chapter is organized to provide information from the current literature that 
deals with cost sharing, its impact on utilization of prescription drugs and issues related 
to asthma controller drug adherence. 
 
In today‟s health care arena prescription drugs play an indispensible role. 
Especially for chronic conditions such as asthma, hypertension, diabetes, prescription 
drugs are instrumental in managing the disease condition and controlling symptoms. 
However, the recent surge in cost of prescription drugs with double digit inflation has 
worried many.
31
 Besides the patients consuming these drugs, major payers such as 
insurance companies are most affected by the rise in cost. In order to offset the increasing 
expenditure on prescription drugs, insurance companies have different strategies to 
design the pharmacy benefit component.  
 
Traditionally researchers considered healthcare as unpleasant and thus not likely 
to be sensitive to price changes. However, the largest social science experiment known as 
RAND Health Insurance Experiment (HIE) demonstrated phenomenon of moral hazard 
even in the field of health insurance by measuring people‟s response to the price of health 
care.
32
  Moral hazard happens when people tend to utilize more expensive medical goods 
and services when they have insurance to cover the cost than when they don‟t have 
insurance. This increase in spending resulting from the lower price to the user because of 
insurance is called „moral hazard‟.2 RAND HIE showed that the people behave in a 
different way, regarding the use of medical care and total spending, when they have 
insurance. The HIE found that people who were receiving free healthcare used 30% more 
healthcare than the people that had deductible.
32
 Same principle applies in case of 
prescription drug coverage as well. Patients having prescription drug coverage are likely 
to use more drugs than they would normally use because they are insulated from the 
actual price. To control the moral hazard and unnecessary spending on healthcare 
services, insurance companies started using cost sharing strategies such as annual 
deductible and copayments. As the drug benefit plans are supplementary to the health 
insurance policy different cost sharing strategies are introduced to the drug plans as well.  
 
Initially some benefit plans implemented closed or very restrictive formularies 
providing insurance coverage to only a limited number of drugs or therapeutic classes. 
This led to major dissatisfaction among patients as well as health care providers such as 
physicians.
33 Because of the unpopularity of these plans, many insurance companies 
adopted a benefit structure covering majority of drugs but classified them into different 
tiers with different co-payment level. The main idea behind this arrangement was to 
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encourage patients to use generic drugs or cheaper brands whenever available. From the 
patient‟s perspective, depending upon what medication they are taking, out of pocket cost 
is determined in the majority of insurance plans. Besides the formulary restrictions, some 
plans also use benefit caps to avoid excessive drug utilization. Benefit caps limit the 
coverage for a specific amount and when the prescription drug expenditure reached that 
limit, patients so not receive any coverage and have to spend the entire cost out of pocket. 
For example Medicare Part D beneficiaries receive coverage only up to $2400 (in 2007) 
and beyond that they have to spend out of pocket until their expenditure reaches $5451.  
Benefit caps also include restrictions on number of prescription drugs covered for an 
individual. Medicaid beneficiaries receiving prescription drug coverage in many states 
are restricted to the number of prescription drugs that can be covered. Benefit caps also 
have a negative impact on utilization of prescription drugs. Soumurai et al.
34
 carried out a 
comparison between prescription drug utilization in New Hampshire (Medicaid plan limit 
of 3 drugs per month per patient) and New Jersey (no such cap existed). They found a 
35% reduction in drug utilization among patients in New Hampshire. 
 
According to the theory of economics, raising the cost sharing levels can have 
following economic effects
35
 1) Utilization: Higher prices are expected to shift patients 
upwards in the demand curve and closer to the economically optimal amount, resulting in 
a decrease in utilization.2) Substitution: If the drug costs are too expensive, patients are 
likely to search for less expensive alternative. For example in case of asthma, patients 
might choose to consume excessive amount of short term relievers to get symptomatic 
relief that are cheaper than the controllers to save money affecting the controller drug 
utilization. 3) Value: A price increase would result in decrease in consumption of drugs 
that are valued lower by the patients and as a result patient would be insensitive to the 
price increase in high value drugs such as life sustaining drugs. However, this effect is 
expected only if patients have adequate information to evaluate cost to benefit ratio 
which is generally not observed.
35
 Therefore even though the controller drugs are 
valuable to the asthma patients having moderate severity, the observed adherence levels 
are still lower.  
 
Therefore it is very important and difficult to maintain the optimum cost sharing 
levels that are high enough to curb the excessive utilization but at the same time are not 
discouraging patients from taking the required amount of medication. 
 
 
2.1 Cost Sharing and Prescription Drugs 
 
The literature on cost sharing for prescription drugs is comprised of a great 
number of studies and articles published in various peer reviewed journals. The various 
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aspects of cost sharing such as co-pay, co-insurance, formularies, tiered structure and 
other methods used to control drug prices make the literature on cost sharing dispersed 
across several fields and not restricted to any specific settings as in case of a medical 
intervention. The literature on cost sharing mainly focuses on the impact of cost sharing 
on: 1) drug spending; 2) adherence/compliance/persistence; and 3) health Outcomes.  
 
 
2.1.1 Drug spending 
 
There are experimental as well as observational studies documenting effects of 
cost sharing levels on healthcare expenditure of prescription drugs at patient level. Data 
published from the RAND Health Insurance Experiment (HIE) is one of the oldest 
published studies in the US documenting the effect of cost sharing on expenditure.
32
 One 
of the important findings from HIE was that individuals subject to higher coinsurance 
level tend to use less care and their response to higher cost sharing in case of prescription 
drugs is similar.
36,37
 A study done by Leibowitz et al. using the data from HIE 
documented that the co-insurance at 95 % can drop the expenditure to 57% of the patients 
receiving free care plan.
4
 Another study published from the HIE showed the patients 
having free care were found to use 85% more antibiotics.
36
  
 
Although the studies based on HIE used relatively older data from RAND study, 
there are number of studies including some recent ones, analyzing the relationship 
between co-insurance and drug spending.
38-40
 Almost all of the studies available in the 
current literature examining the relationship between co insurance and drug spending, 
have successfully documented the reduction in drug expenditure by increasing the co-
insurance levels.  The reduction in expenditure is observed in all age groups including 
children, adults and elderly. Other than the US, studies done in other countries such as 
Canada
38
and Sweden
41
 also have confirmed the finding from the US studies. The 
literature on cost sharing levels and drug spending provides conclusive data on the 
success of implementing cost sharing strategies on limiting the drug spending. Besides 
the cost sharing strategies, several studies have also documented the success of formulary 
restrictions.    
 
 
2.1.2 Adherence and compliance 
 
Adherence and compliance to the various treatments is a key issue in the health 
research literature and studies on them form a vast body of literature. The studies
42-44
  
showing cost effectiveness of prescription drugs over the other health care resources such 
as ED, surgery, hospitalization etc. add to the need to study compliance and adherence 
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with medications. Examples from the current literature, such as cost effectiveness of 
warfarin therapy to prevent stroke,
43
 immunosuppressive drugs for kidney transplants,
44
 
highlight the importance and need of examining drug utilization and factors affecting it to 
achieve the maximum cost effectiveness.
42
  
 
One of the most frequently cited studies on cost sharing and adherence is work 
done by Goldman et al.
45
 In this study they used pharmacy medical claims data covering 
privately insured beneficiaries aged 18-64 in 52 health plans. They examined impact of 
co-payment increase with a broad range of therapeutic classes. They found an inverse 
relationship between co-payment and drug utilization across all therapeutic classes they 
studied. Reduction in drug utilization ranged from 25%-45%. Landsman et al. also 
reported similar findings using Medication Possession Ratio (MPR) as an outcome 
measure. They focused on members from managed care plans and included 9 drug classes 
in their study. Key finding from this study was reduction in MPRs in 7 of 9 drug classes. 
A study done by Ellis et al. examined enrollees with statin prescriptions in a managed 
care organization. They also found that the statin therapy duration decreased with 
increase in copayment from $10 to $20.
46
  
 
However there is a repeatedly cited gap in the literature about studies focusing on 
relationship between cost sharing and adherence or compliance. Many studies examining 
this relationship in the US have focused on Medicaid populations, most of which have no 
or very low cost sharing plans. Outside the U.S. there are several studies published in 
Canada but again in Canada there are very limited variations in cost sharing as compared 
to the US.  
 
Even though the literature has considerable evidence on how increased cost 
sharing results in a decrease in utilization, the current literature on cost sharing lacks 
studies comparing drug classes within a clinical condition and analyzing consequent 
outcomes. Such comparison provides key data for decision makers and formulary 
developers in setting up cost sharing levels for a drug plan. In case of asthma, there are 
very few studies published that examine the link between cost sharing and controller 
regimen adherence.  
 
 
2.1.3 Asthma related healthcare resources utilization outcomes 
 
While studying adherence to different treatment regimens, it is also important to 
study healthcare resources utilization outcomes to confirm that the better adherence is 
translated in to better outcomes. In this section we will review studies that dealt with 
effects of cost sharing on various healthcare resources utilization outcomes. 
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Most of the studies evaluating effect of cost sharing on health outcomes used 
health services utilization as a measure of health outcomes. Although health services 
utilization is not a direct measure of health status or quality of care, increase in utilization 
of services such as emergency room visits, hospitalization, inpatient and outpatient visits 
indicate poor health outcomes. A number of studies
15,47-49
 reported no change in 
utilization of relatively less expensive health services such as physician office visits, 
home health visits and outpatient visits. However the cost sharing changes evaluated in 
these studies were small. Furthermore the studies that did not find any association 
between health services utilization and high cost sharing levels had focus on patients 
suffering from a specific condition such as myocardial infarction. Study done by Pilot et 
al.
15
 measured the effects of prescription drug cost sharing among the patients recently 
hospitalized for acute myocardial infarction and therefore they may have been insensitive 
to the price changes. 
 
In terms of more expensive health services utilization such as inpatient visits or 
ER visits, a study done by Christian-Herman et al.
50
 found that following a large change 
in cost sharing levels in a Medicare HMO plan, the inpatient visits increased 
significantly. Nevertheless the increase was not observed in all the diagnostic groups they 
studied. No significant increase in number of inpatients visits was observed among the 
patients suffering from congestive heart failure or coronary heart disease but on the other 
hand patients suffering from diabetes mellitus had increased number of inpatient visits. 
Another study done by Tamblyn et al.
51
 measured the effects of 25%  raise in copayment 
levels among elderly and welfare recipient in Canada. They found that patients who 
reduced their consumption of essential drugs as a response to the copayment raise had 
greater number of adverse events such as hospitalization, long-term care admission and 
death. 
 
A study conducted by Heisler et al.
13
 measured health outcomes as self reported 
health status, and found that the cost related restrictions among elderly patients were 
associated with decrease in their self-reported health status. They also found association 
of cost related restriction and higher rates of non fatal heart attacks or stroke among those 
with preexisting cardiovascular condition.  
 
In a nutshell, cost sharing levels have mixed effects on the health outcomes such 
as hospitalization, ER visit, outpatient and inpatient visits. The effects vary considerably 
depending upon the disease condition focused in the study.  
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2.2 Cost Sharing and Use of Asthma Medication 
 
 
2.2.1 Brief description of asthma 
 
Asthma is a chronic disorder characterized by inflammation to airway. According 
to the asthma literature, asthma is one of the major causes of work and school absence.
52
 
It has been estimated that costs resulting from lost workdays due to asthma in adults are 
over $800 million per year. An additional $900 million per year is lost because of 
workdays missed by parents caring for children with asthma.
53
 It is also one of the 
common reasons leading to ER visit and hospitalization. According to a study, the 
estimated annual cost of asthma-related hospitalizations is over one billion dollars
54
 also 
the projected yearly cost of asthma-related emergency room visits is close to $300 
million.
53 
From an economic perspective asthma costs approximately $13 billion each 
year in the US.
55
  
 
In terms of mortality, approximately 5000 people die of asthma in the US.
52
 
Based on an estimate by National Center for Environmental Health (NCEH),
56
 there are 
20 million asthma cases in the United States. According to National Institute of Allergy 
and infectious diseases (NIAID),
57
 asthma is the most common chronic condition in 
children and sixth most common chronic condition in general in the United States 
 
Asthma is included as a key component in the respiratory disease chapter of the 
Healthy People 2010 objectives.
58
 These objectives are: 24-1, reduce asthma deaths; 24-
2, reduce hospitalizations for asthma; 24-3, reduce hospital emergency department visits 
for asthma; 24-4, reduce activity limitations among persons with asthma; 24-5, reduce the 
number of school or work days missed by persons with asthma because of their asthma; 
24-6, increase the proportion of persons with asthma who receive formal patient 
education, including information regarding community and self-help resources, as an 
essential part of the management of their condition; 24-7, increase the proportion of 
persons with asthma who receive appropriate asthma care according to the NAEPP 
guidelines; and 24-8, establish in greater than 25 states a surveillance system for tracking 
asthma deaths, illnesses, disabilities, impact of occupational and environmental factors on 
asthma, access to medical care, and asthma management.
58
 
 
 
2.2.2 Asthma severity classification 
 
NHLBI classifies asthma by its severity. The classification based on severity is 
widely used by health care professionals. As asthma treatment choice is largely 
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dependent upon the severity levels, it is useful to briefly review the asthma severity 
levels. These severity levels are based on frequency and severity of asthma symptoms. 
The severity levels according to NHLBI guidelines are outlined in Table 1. 
 
Treatment regimens for children and adults (age 5 and above) are decided based 
on the severity level. Patients having mild intermittent asthma are mostly treated with 
quick-relief medicines only, while patients having severe persistent asthma are treated 
with combination therapy of one or more daily controller medicines along with the use of 
quick-relief medicines as needed. 
 
 
2.2.3 Asthma treatment options 
 
Although asthma can‟t be cured, it can be controlled. Current guidelines also 
recommend treatment for asthma to be focused on controlling the inflammation. 
Monitoring the symptoms and avoiding asthma triggers is considered to be the first step 
in asthma control. Besides avoiding the asthma triggers, guidelines recommend use of 
medications to achieve adequate control. The asthma medications are broadly categorized 
in two types of drugs:  1) quick relief medications, and 2) long term control medications. 
The quick relief medications are short acting bronchodilators such as metaproterenol 
(Alupent, Metaprel), ephedrine, terbutaline (Brethaire) and albuterol (Proventil, 
Ventolin). The long term control medication are inhaled or orally administered anti 
inflammatory steroid such as unisolide (AeroBid), triamcinolone (Azmacort) and 
beclomethasone (Beclovent and Vaceril), Long-acting inhaled 2-agonist (LABA) and 
Leukotrine receptor Antagonist (LTRA),Theophylin etc.  
 
The short acting medications are known to produce symptomatic relief but they 
do not contribute in controlling the chronic inflammation itself in asthma cases. However 
the controller drugs do not show immediate symptomatic relief but help in controlling the 
chronic inflammation itself.  Because of these properties, the short acting dilators are 
being recommended for „as needed‟ or „rescue‟ basis only.8 Patients having persistent 
asthma are advised to take both classes of medication.  
 
Within the controller medications, ICS are proven to be most effective and 
patients are suggested to start with minimum possible dose of ICS therapy. For the 
patients that require more control, guidelines recommend addition of LABA or LTRA to 
the existing dose of ICS. The clinical evidence is not conclusive towards any of these add 
on therapies as the clear dominant over another.   
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Table 1 Asthma severity definition according to NHLBI guidelines
 
 
Asthma 
Severity Intermittent Mild 
Persistent 
Moderate Severe 
Symptoms  ≤ 2 days/week  
> 2 days/week 
but not daily  Daily  
Throughout 
the day  
 
Nighttime 
awakenings  ≤ 2x /month  3-4x/month  
> 1x/week but 
not nightly  
Often 
7x/week  
 
SAB use for 
symptom 
control  ≤ 2 days/week  
> 2 days/week 
but > 1x /day  Daily  
Several 
times per 
day  
 
Interference 
with normal 
activity  None  
Minor 
limitation  
Some 
limitation  
Extremely 
limited  
 
Source: National Heart, Lung and Blood Institute (NHLBI) Clinical practice guidelines, 
Expert Panel Report 2: guidelines for the diagnosis and management of asthma. 2008.
9
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2.2.3.1 Add on therapy with LABA 
 
LABA are potent airway dilators and have a long term effect of chronic 
obstruction caused by asthma. Combining
 
a LABA with an ICS has shown a greater 
improvement in the control of symptoms and
 
in lung function than doubling the dose of 
the ICS
59,60
 A double-blind, randomized, parallel-group study involving 852 patients 
done by Pauwels et el
60
 demonstrated that, the rates of severe and mild exacerbations 
were decreased by 26% to 40%, when formoterol (LABA) was added to the lower dose 
of budesonide (ICS). A study known as GOAL study has confirmed this data by 
conducting a randomized, double-blind, parallel-group
 
study of 3,421 patients with 
uncontrolled asthma.
61
 This study concluded that asthma
 
patients achieved control on
 
asthma symptoms with combination of inhaled Salemterol/fluticasone (LABA+ICS) 
more
 
rapidly and at a lower dose of corticosteroid than with combination of inhaled
 
fluticasone (ICS) alone. 
 
 
2.2.3.2 Add on therapy with LTRA 
 
Leukotriene receptor antagonists (LTRA) are oral medications that act by 
blocking chemical mediators that can lead to inflammation in the airways. LTRA work to 
suppress the airway inflammation and thus produce mild bronchodilation.
62
 Several 
studies have demonstrated efficacy of LTRA along with low doses of ICS  in both adults 
and children.
63,64
 In a study called as COMPACT (Clinical Outcomes with Montelukast 
as a Partner Agent to Corticosteroid Therapy) study, Price et al.
65
 demonstrated the 
efficacy of Montelukast as adjunct to Budesonide (ICS). A recent placebo controlled 
study involving 639 patients on Montelukast (LTRA) for 16 weeks showed decrease in 
the exacerbation frequency.
66
  
 
Even though the safety and efficacy of adding LTRA is established in the current 
literature, the relative efficacy to addition of LABA is questioned. A study done by Busse 
and
 
coworkers
67
 compared the addition of salmeterol (LABA) or zafirlukast (LTRA)
 
to 
low doses of inhaled corticosteroids, found considerably
 
better improvement in lung 
function and symptom control with
 
the addition of the LABA as compared with
 
a LTRA. 
There are also a few studies
68-70
 documenting no additive benefit of LTRA in asthma. 
 
 
2.2.4 Adherence to asthma controller drugs  
 
With the projected $13 billion in direct and indirect costs asthma puts a 
significant burden on US economy. To achieve the best control over asthma, continuous 
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treatment that avoids recurring exacerbations is very important. Although asthma is 
considered as mild illness which should be managed by ambulatory care, the one third of 
the total direct costs is related to emergency department use and hospitalization.
71
 Lately 
a study showed that a large portion of these costs are attributable to the uncontrolled 
asthma. According to the study, primary reason behind the uncontrolled asthma is 
underuse of prescribed therapies such as asthma controller drugs.
71
 Despite the 
recommendations from national guidelines, several studies have reported poor average 
rates of adherence to the controller medications among children
72-74
 as well as adult 
populations
75,76
 suffering from asthma.  
 
A study done by Legorreta et al.
76
 found that overall, adherence to National 
Asthma Education Program (NAEP) guidelines was poor especially with the use of 
preventive drugs. Furthermore the survey respondents that indicated to have asthma 
inhaler, only 54% of them used it daily. Factors such as age (older), duration of asthma 
(longer), increasing current severity of disease, were found to be associated with the 
controller drug use. Jatulis et al.
75
 analyzed adherence to the National Heart, Lung, and 
Blood Institute (NHLBI) guidelines in California and they also found low level of anti-
inflammatory steroids usage despite the emphasis in guidelines.  
 
Lower adherence to the controller drugs is also observed among asthma patient 
with the moderate to severe asthma levels. These patients are in more need of controller 
drugs and lack of controller drug use makes them more vulnerable to the asthma related 
morbidity and mortality. A study called as TNEOR focused on patients with moderate or 
severe asthma categories and found the lack of control in the study population.  
 
The literature on asthma controller medication adherence strongly indicates a 
significant lack of adherence to the controller drugs among asthma patient populations 
across all age groups and asthma severity levels. Also enough evidence was found from 
current literature correlating the lack of adherence to the controller drug with the 
increased consumption of the other healthcare services such as ER visits and worsening 
of the heath status of asthma patients. 
 
 
2.2.5 Adherence measures 
 
In this study we used MPR to measure adherence to the asthma treatment 
regimen. However, various different methods are also used to assess the treatment 
adherence. Traditionally the methods used were pill counting, journals, electronic 
measurement devices, biochemical tracers, questionnaires and more recently analysis of 
pharmacy claims databases are used to assess the adherence to treatment regimens. 
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Studies that use self reported adherence methods ask patients whether they missed doses 
and also reasons if they ever missed any.
77
 Patients are required to mention their current 
prescriptions and the average number of tablets missed per day, week, and month. The 
strength of this method lies in its fast and easy format to administer and it also offers 
thorough information about utilization patterns, patient perception of treatment and 
barriers to access of treatment. However, weakness of this technique is it relies on 
patient‟s memory and honesty. In case of asthma medication utilization Brooks et al.77 
developed a multi-item, self-reported scale to assess patient adherence to the asthma 
inhalers. This scale was supported by the results and because it takes less than five 
minutes to complete, it also demonstrated ease of use. 
 
More recently the widely used method to calculate adherence is to conduct 
retrospective analysis of insurance claims databases. Analyzing claims data has been 
suggested as an appropriate method for several measures such as assessment of quality of 
care, research in pharmacoepidemiology, evaluation of health care appropriateness and 
also cost and utilization studies.
78
 When direct measurement of utilization is not feasible, 
pharmacy claims databases are recommended as most appropriate to measure adherence 
and compliance.
78
 Several studies
78-80
 recommend use of pharmacy claims data to 
evaluate medication compliance and adherence. The adherence rate given by 
administrative data does not provide direct information on medication utilization
 
information, but rather provides evaluation of medication possession. Adherence 
calculations using administrative claims data are based on the assumption that that 
patients use the
 
drug as prescribed from the day of dispensing,
 
and use all medications 
obtained. Therefore administrative data can offer the investigator only an estimate of the
 
maximum possible level of medication utilization.
81
 
 
To measure the adherence using large claims data as source, Sclar et al.
82
 
introduced Medication Possession Ratio (MPR). Followed by their work the MPR in now 
widely accepted as a measurement of drug adherence.
83
 Most of the times the MPR is 
defined as the ratio of „sum of the days' supply of medication‟ to „the total number of 
days in the study period.‟ This ratio yields values ranging from 0 to 1. MPR successfully 
captures the utilization behavior however it fails short to capture characteristics such as 
timeliness and consistency. For example if a patient fills prescription every alternate 
month throughout the year and another patient fills prescription for six months only then 
even though their utilization behavior is different both of them will have exact same 
value for the MPR.  
 
Besides MPR, literature search on adherence measurement using pharmacy claims 
database also showed several methods to measure medication adherence. Some of the 
most frequently cited measures include, Continuous Measure
 
of Medication Acquisition 
25 
(CMA); Continuous Multiple Interval
 
Measure of Oversupply (CMOS); Medication
 
Refill Adherence (MRA); Continuous Measure of Medication Gaps (CMG);
 
Continuous, 
Single Interval Measure of Medication Acquisition
 
(CSA); Proportion of Days Covered 
(PDC); Refill Compliance Rate
 
(RCR); Medication Possession Ratio, modified (MPRm); 
Dates Between
 
Fills Adherence Rate (DBR); and Compliance Rate (CR). Hess et al.
81
 
reviewed studies based on all these measures and concluded that CMA, CMOS. MPR and 
MRA produce identical results in measuring adherence while CMG and PDC produce 
slightly lower and CR, MPRm, RCR and CSA produce higher rates of adherence.  
 
 
2.2.6 Cost sharing and controller drugs utilization 
 
Although cost sharing plays an important role in adherence to the medications for 
chronic conditions, the effect of it among asthma population is not been explored 
extensively. Despite the poor adherence levels are reported abundantly in the current 
literature, there is limited information available on association of it with the cost sharing 
levels. Also the currently available studies focusing on cost sharing and utilization of 
asthma medication did not assess utilization of asthma drugs using adherence measures 
such as MPR. 
 
When searching for the articles on costs sharing effects and asthma controller 
utilization, only two major studies were found in the US. Interestingly, the results from 
both the studies were contradictory to each other. First study found that although the cost 
sharing levels increased from 1995 to 2000, utilization of controller drugs among 
asthmatics was not affected significantly.
25
 Conversely another study done by Goldman 
et al.
45
 explored relationship of cost sharing and utilization of prescription drugs among 
multiple chronic conditions (based on drug classification in the red book) found that 
doubling the cost sharing levels resulted in to 32% drop in overall asthma drug 
utilization. None of these studies specifically focused on the asthmatics with asthma 
severity levels „moderate to severe‟ (patients that need more that one controller drugs). 
Also both the studies did not capture effects of cost sharing levels on health outcomes 
such as emergency room visits, hospitalization and SAB utilization. In terms of cost 
sharing effects on utilization of asthma medications among children, Ungar et al.
84
 did a 
study focusing on cost sharing effects on asthma medication utilization among children in 
Ontario, Canada. In this study they found that the cost sharing levels affected 
consumption of asthma medication among children. Higher cost sharing levels resulted in 
to significantly lower consumption of asthma medications such as controller drugs. 
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2.3 Gaps Addressed by This Study 
 
Work done prior to this study has provided important information about cost 
sharing and its impact on various factors such as drug spending, drug utilization and 
adherence to the treatment regimen. However when it comes to impact of cost sharing on 
adherence to medication within a chronic condition such asthma, there are very few 
studies available. The literature on adherence with asthma controllers has documented the 
lower adherence to controller regimen than the recommended guidelines, but there are a 
limited number of studies examining the association of lower utilization to the out of 
pocket cost. Also the results from previous studies are not consistent with each other and 
do not measure utilization of medications using standardized adherence measures such as 
MPR. Poor adherence to controller regimen is characterized by increased morbidity, 
mortality and increased utilization of health care resources. This gap can be bridged by 
adding more studies to the current literature that establish the link between cost sharing 
and adherence to medication with respect to a particular chronic condition such as 
asthma.  
 
Rising costs of prescription drugs are accelerating the need to introduce greater 
cost sharing in US managed care programs but the information on how successful these 
policies would be to control the overall cost and improve the health status is limited. In 
case of chronic conditions such as asthma, prescription drugs comprise an important part 
of treatment and management of the disease. In this study we focused on the asthma 
patients having moderate to severe asthma levels and analyzed what impact cost sharing 
has on the utilization of controller drugs.    
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Chapter III: Methods 
 
 
The main focus of this study was to evaluate the impact of prescription drug cost 
sharing on utilization of asthma controller medications and to analyze the health 
outcomes associated with the utilization of controller drugs. The study population 
included asthma patients from an administrative claims data within the age group 5-65 
who are stepped up from single controller therapy to the dual controller therapy.   
 
To investigate the impact of cost sharing on adherence to the treatment options we 
utilized retrospective longitudinal study design using administrative claims database. This 
was an observational study and the data for this study came from MarketScan 
commercial database. The study period for each patient started six months prior to the 
patient‟s index medication and continued for six months post index. The asthma patients 
were defined to be diagnosed with „moderate persistent‟ asthma if they were stepped up 
from one controller medication to more than one controller medications. Whether the 
patients were stepped up or not was determined by analyzing their prescription drug 
records.  
 
 
3.1 Study Design 
 
The asthma patients having prescription drug history of only one controller (ICS) 
were selected among them those who were found to have additional controller drug (ICS 
+ LABA or ICS + LTRA) in the claims history were selected for the study. Controller 
drug utilization pattern for these patients before and after getting stepped up was studied 
using MPR as the adherence measure. Presence of additional controller medication (ICS 
+ LABA or ICS + LTRA) was the index date prescription and 6 months prior and after 
the index date defined the study period. Figure 2 illustrates the research design used in 
this study. 
 
To investigate the impact of cost sharing on adherence to the treatment options we 
utilized retrospective longitudinal study design using administrative claims database. This 
was an observational study and the data for this study came from MarketScan 
commercial database. The study period for each patient started six months prior to the 
patient‟s index medication and continued for six months post index (Figure 2). The 
asthma patients were defined to be diagnosed with „moderate persistent‟ asthma if they 
were stepped up from one controller medication to more than one controller medications. 
Whether the patients were stepped up or not was determined by analyzing their 
prescription drug records.  
28 
 
Figure 2 Study design 
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The asthma patients having prescription drug history of only one controller (ICS) 
were selected among them those who were found to have additional controller drug (ICS 
+ LABA or ICS + LTRA) in the claims history were selected for the study. Controller 
drug utilization pattern for these patients before and after getting stepped up was studied 
using MPR as the adherence measure. Presence of additional controller medication (ICS 
+ LABA or ICS + LTRA) was the index date prescription and 6 months prior and after 
the index date defined the study period.  
 
 
3.2 Study Population 
 
For this study we needed patients diagnosed with asthma and who are stepped up 
from a single controller drug (ICS) to a combination of ICS + LABA or LTRA. To 
formulate the final study sample, we applied following inclusion and exclusion criterions. 
 
 
3.2.1 Inclusion criteria 
 
The participants for this study were selected based on their principal or secondary 
diagnostic claim (ICD-9 493.XX) for asthma during the pre index period. All subjects 
included for this study were in the age group from 5 to 65. All asthma patients having at 
least one claim of ICS and no claims for any other controller add-on were recruited for 
the final sampling. Among these patients those that were found to have at least one 
additional prescription of LABA or LTRA along with at least one claim for ICS were 
included in the final sample.  
 
 
3.2.2 Exclusion criteria 
 
To ensure the evaluation of patient outcomes is based on asthma; patients were 
excluded from analysis if they were diagnosed with any of the following conditions in the 
pre or post study period.  The conditions included chronic obstructive pulmonary disease 
(COPD), bronchopulmonary dysplasia and respiratory distress syndrome. Also the 
patients that switched medications from one controller add on to another controller add 
on were excluded from this analysis. Patients not enrolled continuously for the study 
period were also excluded from the study.  
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3.3 Data Source 
 
This study utilized data from the Medstat MarketScan databases (Copyright 2001, 
The Medstat Group, Inc., All Rights Reserved.) The MarketScan databases are based on 
privately insured paid medical and prescription drug claims. The data is collected from 
approximately 45 large employers, health plans, and government and public 
organizations on person specific clinical utilization, expenditures, and enrollment across 
inpatient, outpatient, prescription drug, and carve-out services. Including the commercial 
insurance companies the databases consist of data from almost 100 payers. 
 
The MarketScan Databases are based on a calendar year incurred period and are 
produced as a snapshot in time. The databases are created by combining the standard 
variables of the individual databases (data contributors) and also links between years of 
data are established across all data types. The amount of time between the date of service 
on the claim and the date payment is made, also known as Claims lag periods fluctuate 
considerably across the roughly 100 insurance carriers in MarketScan. Because of this, 
the data are collected when close to 100% of claims have been paid, which takes about 
six months after year end. 
 
Various edits and checks are done to confirm the reasonableness and validity of 
the data. Reasonableness is established by checking the relationship between two or more 
fields against norms. For selected fields, including zip codes, diagnosis codes, procedure 
codes, date(s) of service, gender and age, validity checks are carries out to compare 
recorded values to lists of probable valid values for those fields. The improper coding is 
fixed by flagging and recommending it to the carrier or data processor for quality 
improvement actions.  
 
 
3.4 Measures 
 
According to the theoretical framework of this study we first measured effect of 
cost sharing levels (Exposure variable) on controller drug adherence (intermediate 
outcome) and then measured effect of adherence on health outcomes such as ER visits, 
hospitalization and SAB use (End outcomes). Variables that can be predisposing for 
asthma drug utilization
18
 and also were available in databases included age gender and 
location. Data on race and ethnicity could not be obtained because of the limitation of 
administrative claims databases. Cultural differences, multiple languages influence the 
access of health services. In general because of the cross-cultural difficulties and/or 
language  barriers people belonging to minority groups have been observed to have 
reduced utilization than whites.
26
 It has been documented that the race and ethnicity are 
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major predictors of receiving several procedures and treatments. In one study 
investigators found that out of nine hospital procedures only five procedures were 
significantly less common among African American patients than among Caucasian 
patients. Other AHRQ studies have also revealed that the additional disparities exist for 
various chronic conditions including asthma. Regarding the use of necessary medications 
among pediatric asthma patients compared to 21% of Caucasian patients only 7% 
Afirican American and 2% of Hispanic children were prescribed routine asthma 
medication to prevent the asthma related.  However, as the insurance claims data do not 
allow information on race and ethnicity, the exclusion of this measure is a source of possible 
bias in the estimates due to the correlation of race/ethnicity with measures included in the 
model.  
 
In terms of enabling resources besides the cost sharing levels study included type 
of health plan and pre index healthcare expenditure. For this study, the target population 
represented similar illness level i.e. moderate persistent asthma. In order to control for the 
presence of comorbid conditions which can influence the overall drug utilization
85
, we 
used  Charlson‟s modified comorbodity index86 adapted for administrative claims 
databases.  
 
 
3.4.1 Exposure variable 
 
Cost sharing levels: Cost sharing levels were defined by determining percentage 
of total cost paid by the patients out of pocket. Depending upon the percentage of total 
cost paid out of pocket patients were categorized in to four categories. These categories 
were defined as 0-10%, 11-20%, 21-34% and >35% of total cost paid out of pocket.  
 
 
3.4.2 Outcome variables 
 
Medication Possession Ratio (MPR): To measure the adherence to controller 
drugs, Medication Possession Ratio (MPR) was used. The MPR is a continuous variable 
assessing medication availability over multiple refill intervals. It is calculated by dividing 
the number of days supplied for a given medication by the number of days in the study. 
Possible values for MPR are between 1.0 and 0, 1 indicating highest compliance and 0 
indicating lowest possible compliance. MPR is used frequently in studies as a measure of 
compliance. The MPR provides information about whether the patient is using the proper 
amount of medication in a specific timeframe. In this study, MPR for the medications 
was calculated by dividing the number of days of supply of medication received during 
180 days of follow-up. The relative MPR was determined by calculating the overall 
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median MPR as reference to the individual MPR. For the analysis purpose, based on the 
median, patients were dichotomized in to more or less persistent users (Figure 3). 
 
In terms healthcare resources utilization outcomes, ED visits and hospitalization 
among the study population were used as indicators for the health outcomes. Number of 
ED visits and hospitalizations were calculated for all the study participants and compared 
between the patients having different adherence. The total number of ED visits was 
summed up from the outpatient and inpatient records and total number of hospital stay 
days was calculated based on asthma related inpatient records. Besides ED visits and 
hospitalizations, utilization of SABs was also measured. Over utilization of SAB 
indicates the more frequent asthma symptoms and therefore indicating the poor control 
on the asthma. The current asthma treatment focuses on use of controllers to reduce the 
asthma symptoms which reduces utilization of SABs. 
 
 
3.4.3 Control variables 
 
Age, gender, geographical location, prescription drug expenditure, Charlson‟s co-
morbidity index were used as control variables. Age gender and location provided 
information about predisposing characteristics in the Anderson‟s healthcare utilization 
model. Pre-index total healthcare expenditure (inpatient and outpatient) for six months 
period was calculated for each patient. It served as an enabling factor since it indicates 
patients‟ financial ability to pay the cost out of pocket.  
 
Other than the health care expenditure, type of plan variable was also included as 
enabling variable. Subjects were categorized in to fee-for-service and non-non-fee for 
service plans based on the type of plan they were enrolled in. Non-Fee-for-service plans 
included health maintenance organizations, noncapitated point-of-service plans, preferred 
provider organization, or capitated or partially captitated point-of-service plans. Fee-for-
services plans included basic medical and comprehensive health insurance coverage. 
 
 
3.4.4 Charlson’s comorbidity index 
 
Aggregate comorbidity measures are important to attribute risk factors and 
disease severity of the patient. In order to successfully implement the „need‟ part of 
Anderson‟s healthcare utilization model, it is necessary to attribute severity levels based 
on comorbid conditions. A Charlson Index score,
86
 modified for use in administrative 
databases,
85
 was calculated for each individual patient, using ICD-9
 
CM codes in the 
15 secondary diagnosis field (Table 2).   
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Figure 3 Example of MPR calculation 
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Table 2 Comorbidity weights 
 
Weights Conditions ICD-9 Codes 
 
1 
 
Myocardial infarct 
 
 
410, 411 
 
Congestive heart failure 
 
398, 402, 428 
 
Peripheral vascular disease 
 
440-447 
 
Dementia 
 
290, 291, 294 
 
Cerebrovascular disease 
 
430-433, 435 
 
Chronic pulmonary disease 
 
491-493 
 
Connective tissue disease 
 
710, 714, 725 
 
Ulcer disease 
 
53 l-534 
 
Mild liver disease 
 
571, 573 
 
Hemiplegia 
 
342, 434, 436, 437 
 
Moderate or severe renal disease 
 
403, 404, 580-586 
 
Diabetes 
 
250 
 
Any tumor 
 
140-195 
 
Leukemia 
 
204-208 
 
Lymphoma 
 
200, 202, 203 
3 Moderate or severe liver disease 
 
070, 570, 572 
6 Metastatic solid tumor 196-199 
 
Source: D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the 
Charlson comorbidity index with administrative data bases. Journal of Clinical 
Epidemiology 1996 December; 49(12):1429-33.
85
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The Charlson comorbidity index was originally designed as a
 
measure of the risk 
of 1-year mortality attributable to comorbidity
 
in a longitudinal study of general 
hospitalized patients. The measure
 
was then validated for the same outcome in a cohort of 
breast
 
cancer patients. Cox proportional hazard modeling was used to create its contents 
and weighting scheme.
86
 Later on it was
 
adapted in a way that International 
Classification of
 
Diseases, Ninth Revision (ICD-9), codes could be used to compute
 
the 
Charlson Comorbidity Index with existing administrative
 
data
85
.  Using the ICD codes 
from the outpatient‟s claims for the primary or secondary diagnoses by the study 
population, weights were applied and individual comorbidity scores were assigned to all 
the study participants  
 
 
3.5 Statistical Analysis 
 
 
3.5.1 Cost sharing levels and adherence  
 
Accurately assessing the impact of cost sharing levels on adherence with 
controller drugs requires rich data source and advanced statistical techniques. Regression 
modeling, statistical tests such as student t test and use of statistical software SAS 
(version 9.1) helped to achieve the results for this study. This methodology provided 
important information that will be essential in targeting future strategies to improve the 
controller drug utilization among asthma population.  
 
To quantify the change in Medication Possession Ratio (adherence measure) with 
respect to increase in cost sharing level, multivariate least square linear regression model 
was built. All study participants were categorized into cost sharing levels (0-10%, 11-
20%, 21-35% and >36%) calculated by percentage of total cost of a drug paid out of 
pocket and the change in adherence was evaluated. Cost sharing levels was the 
independent variable of interest in this model. The model was adjusted for 
covariates/independent variables available from the data such as gender, age past year 
expenditure on prescription drugs and Charlson comorbidity index. Age was squared and 
also included in the model as usually age has a curvilinear relationship with utilization of 
health services. The past year expenditure was log transformed to reduce the influence of 
outliers. This helped to reduce skewness of the distribution and bring it close to normal 
distribution. 
 
Yi = β0 + β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5    
Where,   i = 1,..., n   
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Y = Adherence to controller drugs (MPR) 
x1 = Cost sharing levels
 
x2 = Gender
 
x3 = Age
 
x4 = Past year expenditure
 
x5 = Charlson comorbidity index 
 
A similar regression model was built to analyze if the regression coefficient varies 
across patients that used ICS+LABA and ICS+LTRA.  
 
 
3.5.2 Adherence and resource utilization outcomes  
 
Once the relationship between cost sharing levels and adherence to controller 
drugs was analyzed, the asthma related health care services utilization outcomes 
relationship with the adherence level was analyzed by controlling the covariates. Since 
the adherence is also a function of some variables, it is an endogenous variable. The 
endogenous explanatory variable makes a non-zero correlation with the error term in the 
health care utilization regression.  
 
In cases where such correlation occurs ordinary linear regression models 
generally produces biased estimates. To overcome this problem, if an instrument is 
available and used, consistent estimates may still be obtained. An instrument is a variable 
that correlated with the endogenous explanatory variable but does not itself have any 
direct impact on healthcare utilization variables.
87
 
 
So finally to estimate the unbiased results, a two stage least square regression 
equation was built. In the first stage, the endogenous adherence variable was regressed on 
prescription drug cost sharing plus all explanatory variables in the health care service 
utilization regression equation. Since the cost sharing levels for prescription drug may 
influence adherence with controller drugs, it may not have any direct influence on other 
resource utilization such as ER visits and hospitalization. Thus, it qualifies as an 
instrument. From this equation, the inverse mills ration was obtained. In the second stage, 
each healthcare service utilization variables were regressed on the adherence variable, 
and other covariates plus the inverse mills ratio created in the first stage. 
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Yi = β0 + β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5 + β5 xi6 + ei   
Where,   i = 1,..., n   
Y = Number of ER Visits 
x1 = Predicted value of MPR 
x2 = Gender 
x3 = Age 
x4 = (Age)
2 
x5 = Log (Past year expenditure)
 
x6 = Charlson comorbidity index 
 
Yi = β0 +β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5+ β5 xi6 + ei     
Where,   i = 1,..., n   
Y = Hospitalization  
x1 = Predicted value of MPR  
x2 = Gender
 
x3 = Age
 
x4 = (Age)
2
 
x5 = Log (Past year expenditure)
 
x6 = Charlson comorbidity index 
 
Yi = β0 + β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5 + β5 xi6 + ei     
Where,   i = 1,..., n   
Y = SAB use 
x1 = Predicted value of MPR  
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x2 = Gender
 
x3 = Age 
x4 = (Age)
2
 
x5 = Log (Past year expenditure)
 
x6 = Charlson comorbidity index 
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Chapter IV: Results 
 
 
4.1 Sample Selection and Sample Characteristics 
 
 Based on the diagnostic codes on the outpatient‟s claims data, total 89,766 
patients were identified to have asthma. After analyzing prescription drugs claims of 
these patients for the recruiting period (July 2000 to July 2001), 7,941 patients were 
found to use either LABA or LTRA prescription(s). Prescription drug claims for these 
patients were further analyzed for six months prior to the first occurrence of either LABA 
or LTRA prescription and 3.466 patients were found to have no evidence of LABA or 
LTRA use and also evidence of ICS use.  
 
These patients were categorized as stepped up patients and by analyzing their 
enrollment records only those patients were selected that were continuously enrolled in a 
health plan for the entire study period (pre-index and post-index period). Further, patients 
that had evidence of switching from one add on to another during the post index period 
were excluded from the study. Patients that were diagnosed with chronic obstructive 
pulmonary disease (COPD), bronchopulmonary dysplasia and respiratory distress 
syndrome were also excluded. Finally patients below age 5 were excluded to form the 
final study sample of 1447 patients (Table 3).   
 
In terms of demographic characteristics (Table  4), the study sample had more 
females than males with average age of 37(SD 19.17). Majority of them were located in 
north central (35.52%), north east (25.22%) and south (33.31%) with relatively lower 
percentage of residents (5.94%) from the west region. In terms of Charlson‟s co-
morbidity scores, values ranged from minimum 0 to maximum 11. Charlson‟s 
comorbidity scores were assigned based on the number of comorbid conditions present 
besides asthma multiplied by weights assigned to each comorbid condition  Most number 
of subjects had a comorbidity score in the range of 0-3 while about 10% of the total study 
population had a comorbidity score higher than 3.  
 
The cost sharing levels were defined by determining percentage of total cost paid 
by the patients out of pocket Patients were categorized into four categories.:  0-10%, 11-
20%, 21-34% and >35% of total cost paid out of pocket. Patients that paid more than 
35% out of pocket were lesser in number (3.73%) while all other categories had close to 
30% patients.  
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Table 3 Sample selection criteria 
 
Sample Selection Criteria  
Number of 
Patients Dropped 
Number of Patients 
Remaining 
 
Total number of patients with an asthma 
diagnosis on a outpatient claim 0 89,766 
Evidence of using ICS 65,470 24,296 
 
Evidence of LABA/LTRA in the 
recruiting period, but no evidence of 
LABA/LTRA use in the pre-index 
period 21,510 2,339 
 
Continuous enrollment in the total study 
period 447 1,892  
 
No evidence of switching from one add-
on drug to another add-on drug 248  1,644 
 
No evidence of other respiratory 
conditions 97 1,547 
 
Patients between age 5 and 65 100 1,447 
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Table 4 Sample characteristics 
 
Variable Asthma Patients (% or $) 
  Gender (%) 
 Male  582 (40.22)  
Female 865 (59.78)  
Total  1,447 
  Mean Age (SD) 37.27 (19.17)  
  Geographical Region (%) 
 Northeast 365 (25.22)  
North Central 514 (35.52)  
South 482 (33.31)  
West  86  (5.94)  
  Pre-Index Average 
Healthcare Expenditure 
(SD) $1,623.51 ($3,597.08) 
Comorbidity Score (%) 
 0 682 (41.13) 
1 427 (29.51) 
2 201 (13.89) 
3 78 (5.39) 
4 and above 59 (4.13) 
Cost Sharing Levels (%)  
 
0-10%  433 (29.94)  
11-20%  485 (33.54)  
21-35%  474 (32.78)  
36% and more  54  (3.73)  
Plan Type (%) 
 
Non-Fee-for-Service Plan 1,125 (77.75) 
Fee-for-Service Plan 322 (22.25) 
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4.2 Multivariate Regression Analysis 
 
Multivariate regression analysis carried out to analyze relationship between cost 
sharing levels and combined adherence to ICS+LABA/LTRA.  This analysis (Table 5) 
showed a negative association between cost sharing levels and adherence to the controller 
regimen among the study population. Multiple dummy variables with different cost 
sharing levels were used to analyze effect of cost sharing levels (0-10%, 11-20%, 21-35% 
and >36%) on adherence to the controller drugs.  
 
The 0-10% cost sharing level was used as reference group and change in the 
adherence was measured. Results showed that patients having co-pay levels at 11-20% 
had a 5% decrease (β = -0.05153 p = 0.006) in adherence while patients having 21-35% 
co-pay had a 12% decrease in adherence compared to the patients having 0-10% co-pay.  
 
Asthma patient that paid more than 36% cost out of pocket had the lowest rate of 
adherence (β = -0.1906 p = <0.001) demonstrating overall drop in adherence with 
increase in co-pay levels. The null hypothesis for this analysis was that the adherence 
levels would not be affected by changes in the cost sharing. However, since significant 
drop in adherence with respect to the cost sharing levels was observed, null hypothesis 
was rejected.  
 
In terms of other demographic characteristics, compared to the patients from 
south, patients in all other regions (Northeast - β = 0.029 p = 0.0649 North Central β = 
0.0571 p = 0.004 West β =0.081 p = 0.0027) were found to be more adherent to the ICS 
regimen. Charlson‟s co-morbidity score (β = 0.004 p =0.346) and gender (β = -0.01995 p 
= 0.1207) had a statistically insignificant association with the adherence while pre index 
health care expenditure had a negative association (β = -0.0051 p = 0.0207) Compared to 
fee for service plans, patients in non fee for service plans were found to have better 
adherence. (β = -0.0966 -p = <0.001) The parameter estimate for age variable was 
negative (β = -0.0061 -p = <0.001) while the estimate for age square was positive (β = -
0.00011 -p = < 0.001) showing a curvilinear relationship with the controller adherence. 
 
Analysis of ICS adherence and cost sharing association before and after index 
period (Table 6) showed an increased magnitude of negative association in post index 
period (β -0.005   p = <0.001).  The null hypothesis here was that there would not be any 
change in controller adherence with respect to the cost sharing levels. However as the 
analysis showed an increased magnitude of negative association, showing an increased 
sensitivity to the cost sharing the null hypothesis was rejected    
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Table 5 Multivariate regression: association between cost sharing and combined 
controller (ICS+LABA/ LTRA) adherence 
 
Variable Parameter Estimate P-Value 
Cost sharing level 
  
0-10% (Reference) 
  11-20% -0.05153 0.006
*
 
21-35% -0.12096 <.0001
*
 
36% and more -0.19069 <.0001
*
 
Age -0.00661 <.0001
*
 
Age Square 0.00011483 <.0001
*
 
Gender 
  
Male (Reference) 
  Female -0.01995 0.1207 
Region 
  
South (Reference) 
  
Northeast 0.02956 0.0649 
North Central 0.05714 0.0004
*
 
West 0.08105 0.0027
*
 
Pre-Index Healthcare 
Expenditure -0.0051 0.0207
*
 
Comorbidity Index 0.00486 0.3467 
Plan Type 
  Non Fee-for-Service plan 
(Reference) 
  Fee- for-Service Plan -0.0966 <.0001
*
 
 
* Statistically significant at 0.05 alpha 
n: 1442  R-Square: 0.47  
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Table 6 Multivariate regression: association between cost sharing and steroid adherence 
in the pre-index and post-index period 
 
 
ICS Adherence Pre-index ICS Adherence Post-index 
Variable 
Parameter 
Estimate P-Value 
Parameter 
Estimate P-Value 
Cost Sharing -0.00484 <.0001
*
 -0.00566 <.0001
*
 
Age -0.00075245 0.634 -0.00184 0.2881 
Age Square 0.00004453 0.0488
*
 0.00006515 0.0085 
Gender 
    Male (Reference) 
    Female -0.0159 0.2158 -0.01704 0.2254 
Region 
    South (Reference) 
    Northeast 0.02487 0.1201 0.01631 0.3514 
North Central 0.05469 0.0007
*
 0.05487 0.0018
*
 
West 0.08253 0.0022
*
 0.08057 0.0064
*
 
Pre-Index Healthcare 
Expenditure -0.00586 0.0078
*
 -0.0062 0.0101
*
 
Comorbidity Index 0.004 0.4382 0.00288 0.61 
Plan Type 
    Non-Fee-for-Service 
(Reference) 
    Fee- for-Service Plan -0.08797 <.0001
*
 -0.10568 <.0001
*
 
 
* Statistically significant at 0.05 alpha 
ICS = Inhaled Corticosteroids 
n: 1442  R-Square: 0.48        
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4.3 Comparison of Regression Co-efficient between ICS+LABA and 
ICS+LTRA 
 
To compare the change adherence levels with respect to cost sharing between 
ICS+LABA and ICS+LTRA users, two regression models were built to obtain two 
different regression coefficients. Both the models included cost sharing as a continuous 
variable. The total sample had 898 (62.0%) patients that were prescribed ICS+LABA 
while 549(37.94%) patients were prescribed ICS+LTRA therapy (Table 7).   
 
In terms of pre-index characteristics, subjects in ICS+LTRA group were less 
likely to be females and younger in age than the ICS+LABA group.  These differences 
were appropriately controlled in the multivariate regression models.  
 
 ICA+ LABA cohort produced a slightly lower regression coefficient (β = -0.0042 
p = <0.001) than the ICS+LTRA cohort (β = -0.005 p = <0.002) demonstrating the 
difference in adherence levels as a response to co pay level (Table 8). Both the 
coefficients were tested using Student t-test to find out if the difference between them is 
statistically significant. The t-test result showed a statistically significant difference 
between these two values.  
 
The null hypothesis in this case was that there would not be any difference in the 
cost sensitivity for these two options. However, since there was significant difference in 
the cost sensitivity between the ICS+LABA and ICS+LTRA sub groups, null hypothesis 
was rejected.   
 
 
4.4 Adherence and Healthcare Resources Utilization 
 
Among the study population, 140 (9.68%) patients had at least one asthma related 
ER visit in the post index period while 67 (4.6%) patients had at least one asthma related 
hospitalization in the post index period (Table 9).  
 
Based on the data from outpatient, inpatient and prescription drug claims, total 
number of ER visits, days spent in hospital and number of SAB prescriptions used was 
calculated for each individual patient. About 9% of the patients in each cohort had at least 
one ER visit. Close to 4% patients in ICS+LABA cohort had at least one hospitalization 
while 5.46% of patients had at least one hospitalization. SAB use was also similar in two 
cohorts with average of 2.12 prescriptions in ICS+LABA group and 2.47 prescriptions in 
ICS+LTRA group. Controller adherence was slightly better (48% MPR) in ICS+LTRA 
group compared to the ICS+LABA group (43% MPR) 
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Table 7 Pre-index characteristics for ICS+LABA and ICS+LTRA cohorts 
 
Variable ICS + LABA ICS+ LTRA P-Value 
 
Gender (%) 
  
0.002
a
 
Male  328 (36.53 ) 254 (46.27) 
 Female  570 (63.47) 295 (53.73) 
 Total  898 549 
 Mean Age  42.35 28.77 <0.001
b
 
Geographical Region 
(%) 
  
0.3703
a
 
Northeast 219 (24.39 ) 146 (26.59) 
 North Central 315  (35.08 ) 199 (36.25) 
 South 313  (34.86 ) 169 (30.78) 
 West 51  (5.68) 35 (6.19 ) 
     Pre-Index Average 
healthcare expenditure  1,706.41 1,487.91 0.2918
b
 
 
Comorbidity Score (%) 
  
0.0407
a
 
0 446 (49.6) 236 (42.9) 
 1 263 (29.28) 164 (29.8) 
 2 113 (12.5) 88 (16.02) 
 3 40 (4.4) 38 (6.9) 
 4 and above 36 (4.0) 23 (4.18) 
 Cost sharing levels (%)  
  
<0.001
a
 
0-10%  254 (28.29) 117 (21.31) 
 
11-20%  356 (39.64) 176 (32.06) 
 21-35%  257 (28.62) 237 (43.17) 
 36% and more  31 (3.45) 19 (3.46) 
 Plan Type (%) 
  
0.1458
a
 
Non-Fee-for-Service Plan 687 (76.5) 438 (79.78) 
 Fee-for-Service Plan 211 (23.5) 111 (20.22) 
  
a. Pearson‟s Chi-square test 
b. Student‟s t-test 
ICS = Inhaled Corticosteroids  
LABA= Long-Acting Beta-2 Agonists  
LTRA= Leukotrine receptor Antagonist  
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Table 8 Multivariate regression: association between cost sharing and LABA/LTRA 
adherence 
 
 
ICS + LABA  ICS + LTRA  
Variable 
Parameter 
Estimate  P-Value  
Parameter 
Estimate  P-Value  
Cost sharing -0.00427 <.0001
*
  -0.005 0.0002
*
  
Age 0.00215 <.0001
*
  0.00103 0.1198 
 
Gender 
    Male (Reference) 
    Female -0.04687 0.0127 -0.0173 0.5145 
 
Region 
    South (Reference) 
    Northeast -0.00808 0.733 0.06513 0.0548 
North Central 0.03558 0.1256 0.05034 0.1385 
West 0.10226 0.0106
*
  0.02431 0.6636 
Pre-Index Healthcare 
Expenditure -0.00058885 0.8285 -0.00595 0.1485 
Comorbidity Index 0.00333 0.6764 0.00854 0.3962 
Plan Type 
    
Non-Fee-for-Service Plan 
(Reference) 
    
Fee- for-Service Plan -0.09344 0.0001
*
  -0.06162 0.0923 
 
* Statistically significant at 0.05 alpha 
ICS = Inhaled Corticosteroids  
LABA= Long-Acting Beta-2 Agonists  
LTRA= Leukotrine receptor Antagonist  
n: 1442  R-Square: 0.35 
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Table 9 Unadjusted healthcare utilization for the post-index follow up period 
 
Description ICS+LABA ICS+LTRA 
 
Patients having at least one ER 
visit (%) 84 (9.3) 50 (9.1) 
Patients having at least one 
hospitalization (%) 37 (4.12) 30 (5.46) 
 
Average number of SAB 
prescriptions (SD) 2.12 (5.05 ) 2.47( 4.31) 
 
Adherence (SD) 0.43( 0.23) 0.48 (0.24 ) 
 
ICS = Inhaled Corticosteroids  
LABA = Long-Acting Beta-2 Agonists  
LTRA = Leukotrine receptor Antagonist  
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A multivariate two stage regression model was built to quantify the relationship 
between adherence and ER visits. Results from the regression model (Table 10) showed 
an overall drop in number of ER visits with the increase in adherence levels (β = -0.634 p 
= <0.05). However when analyzed the similar association within ICS+LABA and 
ICS+LTRA cohorts separately, only ICS+LABA (β = -0.1244 p = 0.0075) group showed 
a drop in ER visits with respect to the adherence level (Table 11).  Regarding the 
covariates used in this model only comorbidity index (β = -0.02011 p = <0.001) had a 
significant association with the ER visits. 
 
Another multivariate two stage regression model was built to quantify the 
relationship between adherence and hospitalization. Results from the regression model 
(Table 12) showed no significant relationship between controller adherence and hospital 
stay (β = -0.1140 p = 0.2286). When the same relationship was analyzed separately for 
ICS+LABA(β = -0.08789 p = 0.2257) and ICS+LTRA(β = 0.1768 p = 0.374), none of the 
models yielded significant association between controller adherence and hospital stay 
(Table 13) Among the other predictors only comorbidity score (β = -0.0408 p = 0.0045) 
was found to be associated with the hospital stay. 
 
To analyze the association between SAB use and controller adherence a similar 
multivariate two stage regression model was built (Table 14). The same relationship was 
analyzed separately for ICS+LABA(β = -0.0090 p = 0.9553) and ICS+LTRA(β = -0.0519 
p = 0.6557), none of the models yielded significant association between controller 
adherence and SAB use (Table 15) This model also did not show any significant 
association between controller adherence and SAB use (β = 0.02498 p = 0.7971) and 
among the other predictors only age (β = -0.02881 p =0.008) and age square (β = 0.00046 
p = 0.0026) were significantly associated with the controller adherence. 
 
The null hypotheses for all three health services utilization outcomes expected 
reduction in the utilization with respect to the controller adherence. However, only in 
case of ER visits reduction in utilization was observed to be significantly associated with 
the reduction in utilization and therefore the null hypothesis was rejected only in case of 
ER visits. In case of hospital stay and SAB use the null hypothesis could not be rejected.  
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Table 10 Multivariate two stage regression: association between controller adherence and 
number of ER visits 
 
Variable Parameter Estimate P-Value 
Adherence -0.06341 0.05
*
 
Age 0.000116 0.9739 
Age Square -0.00002 0.6293 
Gender   
Male (Reference)   
Female -0.00213 0.9408 
Region   
South (Reference)   
Northeast -0.01252 0.7258 
North Central 0.007575 0.8265 
West -0.02653 0.6591 
Pre-Index Healthcare 
Expenditure 
-0.00648 0.5745 
Comorbidity Index 0.020117 <.0001
*
 
Plan Type   
Non-Fee-for-Service Plan 
(Reference)   
Fee- for-Service Plan 0.01314 0.7173 
 
* Statistically significant at 0.05 alpha 
n: 1442  R-Square: 0.42 
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Table 11 Multivariate two stage regression: association between controller adherence and 
ER visits among ICS+LABA and ICS+LTRA cohorts 
 
 
ICS + LABA ICS+ LTRA 
Variable 
Parameter 
Estimate P-Value 
Parameter 
Estimate P-Value 
 -0.12448 0.0075
*
 -0.0198 0.6961 Adherence 
 
Age 0.00293 0.533 -0.0017 0.7919 
 
Age Square -0.00005245 0.4049 -0.00000444 0.964 
 
Gender 
    Male (Reference) 
    Female -0.00796 0.8152 0.00019083 0.997 
 
Region 
    South (Reference) 
    Northeast 0.01075 0.7987 -0.06388 0.326 
North Central 0.06199 0.1268 -0.07464 0.2377 
West -0.02247 0.7542 -0.04219 0.6935 
 
Pre-Index Healthcare 
Expenditure 0.01075 0.4528 -0.02747 0.1601 
 
Comorbidity Index 0.0182 0.0012
*
 0.02337 0.0142
*
 
 
Plan Type 
    Non Fee-for-Service Plan 
(Reference) 
    Fee- for-Service Plan -0.02303 0.5864 0.06984 0.2982 
 
* Statistically significant at 0.05 alpha 
ICS = Inhaled Corticosteroids  
LABA= Long-Acting Beta-2 Agonists  
LTRA = Leukotrine receptor Antagonist  
n: 1442  R-Square: 0.44 
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Table 12 Multivariate two stage regression: association between controller adherence and 
number of hospital days 
 
Variable Parameter Estimate P-Value 
Adherence 0.114093 0.2286 
Age -0.01037 0.317 
Age Square 0.000183 0.2175 
Gender 
  
Male (Reference) 
  Female 0.078549 0.3493 
Region 
  
South (Reference) 
  Northeast -0.11808 0.2579 
North Central -0.17505 0.0833 
West -0.07082 0.687 
Pre-Index Healthcare 
Expenditure 0.023119 0.4929 
Comorbidity Index 0.040898 0.0045
*
 
Plan Type 
  Non Fee-for-Service Plan 
(Reference) 
  
Fee- For-Service Plan -0.0396 0.7089 
 
* Statistically significant at 0.05 alpha 
n: 1442  R-Square: 0.23 
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Table 13 Multivariate two stage regression: association between controller adherence and 
hospital stay among ICS+LABA and ICS+LTRA cohorts 
 
 
ICS + LABA ICS+ LTRA 
Variable 
Parameter 
Estimate P-Value Parameter Estimate P-Value 
Adherence -0.08789 0.2257 0.1768 0.374 
 
Age -0.01012 0.1679 -0.02182 0.388 
 
Age Square 0.00014782 0.1331 0.00045309 0.2405 
Gender 
    Male (Reference) 
    Female 0.00835 0.8752 0.18954 0.3473 
Region 
    South (Reference) 
    Northeast 0.00672 0.9187 -0.354 0.1655 
North Central -0.03332 0.5991 -0.43851 0.0772 
West 0.01053 0.9251 -0.2096 0.6177 
 
Pre-Index Healthcare 
Expenditure -0.01872 0.4029 0.06441 0.4008 
Comorbidity Index 0.03108 0.0004
*
 0.05729 0.1249 
Plan Type 
    Non Fee-for-Service 
Plan (Reference) 
    Fee- for-Service Plan -0.0151 0.8194 -0.12201 0.6431 
 
* Statistically significant at 0.05 alpha 
ICS = Inhaled Corticosteroids  
LABA= Long-Acting Beta-2 Agonists  
LTRA= Leukotrine receptor Antagonist 
n: 1442  R-Square: 0.22 
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Table 14 Multivariate two stage regression: association between controller adherence and 
SAB refills 
 
Variable Parameter Estimate P-Value 
Adherence 0.024983 0.7971 
Age -0.02881 0.0068
*
 
Age Square 0.00046 0.0026
*
 
Gender 
  Male (Reference) 
  Female -0.06494 0.4507 
Region 
  South (Reference) 
  Northeast -0.17179 0.1087 
North Central -0.15794 0.1277 
West -0.10106 0.5752 
 
Pre-Index Healthcare 
Expenditure 0.000428 0.9901 
Comorbidity Index 0.006535 0.6579 
Plan Type 
  Non-Fee-for-Service Plan 
(Reference) 
  Fee- for-Service Plan 0.020267 0.8522 
 
* Statistically significant at 0.05 alpha 
n: 1442  R-Square: 0.31 
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Table 15 Multivariate two stage regression: association between controller adherence and 
SAB refills among ICS+LABA and ICS+LTRA cohorts 
 
 
ICS + LABA ICS+ LTRA 
Variable 
Parameter 
Estimate P-Value 
Parameter 
Estimate P-Value 
 
Adherence -0.00906 0.9553 -0.05194 0.6567 
Age -0.01974 0.2275 -0.0441 0.0031
*
 
Age Square 0.00033133 0.1313 0.00075351 0.0009 
Gender 
    Male (Reference) 
    Female -0.11824 0.3191 0.00011065 0.9993 
Region 
    South (Reference) 
    Northeast -0.25652 0.081 -0.05493 0.7141 
North Central -0.10307 0.466 -0.24709 0.0903 
West -0.34779 0.1644 0.27303 0.2689 
 
Pre-Index Healthcare 
Expenditure -0.00884 0.6507 0.03117 0.1554 
 -0.02794 0.5756 0.02121 0.6379 Comorbidity Index 
Plan Type 
    Non Fee-for-Service 
plan (Reference) 
    Fee- for-Service Plan -0.05342 0.7172 0.12092 0.4347 
 
* Statistically significant at 0.05 alpha 
ICS = Inhaled Corticosteroids  
LABA= Long-Acting Beta-2 Agonists  
LTRA = Leukotrine receptor Antagonist 
n: 1442  R-Square: 0.37 
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Chapter V: Discussion 
 
 
Prescription drug cost sharing has been used as an effective strategy to control 
prescription drug costs in both privately and publicly funded health plans. Although this 
strategy has shown reduction in expenditure, the current literature has reported its 
negative effects such as treatment disruption or discontinuation among chronically ill 
patients.
35
 Additionally, higher levels of cost sharing can have considerable effects on the 
use of essential or maintenance medications, and outcomes associated with care. The 
literature on cost sharing clearly indicates that higher levels of cost sharing result in a 
larger financial burden to the patient. Currently the majority of studies dealing with the 
effects of cost sharing focus on homogeneous populations. However, different groups of 
patients especially those who are chronically ill are affected differently and therefore 
there is strong need to analyze effects of cost sharing levels on varied subgroups of 
individuals.
35
 The present study aimed at determining impact of cost sharing levels on 
adherence to the treatment regimen in case of asthma patients with moderate persistent 
asthma.  
 
The final sample for this study had more females than males.  This has been 
consistent with the existing literature on asthma drug therapy.  Despite the guidelines‟ 
preference for ICS + LABA combination as a step up therapy, a significant percentage of 
asthma patients were found to be on ICS +LTRA. This showed the fact that leukotrine 
receptor modifiers still have a place in current asthma medication treatment. Other 
demographics such as age and geographical region were consistent with the asthma 
literature except for region west which had a very low number of study subjects. 
 
 
5.1. Cost Sharing and Adherence  
 
Results of the study showed an overall negative relationship between cost sharing 
and adherence to controller drug therapy.  It is clear from the results that among the study 
population, as the cost sharing goes up, adherence levels start dropping significantly. 
Compared to the patients that had cost sharing at 0-10% level, as the cost sharing went up 
adherence dropped gradually at every increase in cost sharing. This effect is more 
prominent when cost sharing levels are at maximum level. Adherence dropped by 19% 
for patients that had cost sharing at 35% and above (Table1). Analysis also revealed a 
negative relationship between cost sharing levels and adherence before and after they are 
stepped up to dual controller therapy. When compared for the cost sensitivity to ICS 
before and after, patients showed slightly higher sensitivity to ICS after getting stepped to 
the dual controller therapy. According to the national guidelines patients are stepped up 
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to dual controller therapy when their asthma is not controlled by ICS alone. In such 
patients asthma severity level is higher and therefore there is a greater need to be 
adherent to the prescribed regimen. However, as the patient has to purchase two 
medications instead of one, the cost burden is greater. Patients with uncontrolled asthma 
that were stepped up to the dual controller therapy had a drop in adherence in after they 
were stepped up to dual controller therapy. Therefore it can be concluded that the 
increased cost burden plays a significant role in case of these patients.  
 
Comparative analysis between ICS+LABA and ICS+LTRA showed that patients 
in ICS+LTRA are more sensitive to cost sharing levels than the patients using 
ICS+LABA. As shown in Table 8 the drop in adherence with respect to cost sharing was 
greater in case of ICS+LTRA (β = -0.005 p = 0.0002) compared to ICS+LABA (β = 
0.00427 p <0.0001) subgroup. One probable reason behind that could be the difference in 
mechanisms of these two add-on drugs. Both the combinations ICS/LTRA ICS/LABA‟ 
have demonstrated improvements in terms of asthma symptoms and exacerbation rates
117
; 
however, both combinations achieve symptomatic relief through different mechanisms. 
This difference is mainly attributed to the fact that ICS/LABA combination focuses on 
improving the lung function whereas; ICS/LTRA‟s combination focuses on 
complementary suppression of the airway inflammation. Because of this property LABA 
are known to produce some symptomatic relief along with the controlling the condition 
however LTRA does not produce any symptomatic relief along with controlling the 
inflammation. It could be possible that because of this characteristic patients may value 
ICS + LABA combination slightly more that the ICS+LTRA combination and therefore 
they are more sensitive to cost sharing levels in case ICS+LTRA.  
 
In general, despite the recommended guidelines on use of controller drugs, the 
data showed poor adherence levels with all the controller drugs which were included in 
this study. The average adherence was 0.48 for the combined controller dug therapy. This 
is in agreement with the existing literature. Besides the cost sharing, type of insurance 
plan was also significantly associated with the adherence to controller regimen. Patients 
in non fee for service plans such as HMO and PPO had better adherence to the all 
regimens while patients in fee for service plans were less adherent to the prescribed 
regimen. This underlines the fact that managed care plans are doing better in terms of 
adherence to the controller drugs. A study done by Crown et al.
25
 also found that the 
patients in fee for service plan had a lower adherence to the controller drugs.  
 
Further the study also found that geographical region was a significant predictor 
of the controller drug use. Compared to all other regions, subjects from south were found 
to be less adherent to the prescribed therapy. Regarding the age of patients, a curvilinear 
relationship was observed. Inclusion of age and age square variables revealed that 
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initially the adherence levels went up as the age was increased and after a certain age 
adherence levels started dropping with the increase in age. Gender was not found to be 
associated with the controller adherence. The pre-index healthcare expenditure had a 
negative correlation with the controller adherence which shows that higher the economic 
burden could put budget constraints leading to decreased controller adherence. 
 
 
5.2 Health Services Utilization Outcomes 
 
The study further analyzed the association of adherence and asthma related health 
services utilization such as ER visits, hospital stay and use of SAB. Although health 
services utilization is not a direct measure of health status or quality of care, increase in 
utilization of services such as emergency room visits, hospitalization, inpatient and 
outpatient visits indicate poor health outcomes. Results from this analysis indicated 
mixed effects regarding the health services utilization. The number of asthma related ER 
visits were found to be associated with the adherence levels. In general the patients that 
had higher adherence to the controller regimen had less ER visits after controlling for 
other factors. Association of higher adherence values to the lower number of ER visits 
indirectly indicates the better control of asthma. However when the similar analysis was 
done by separating the study population in to two groups based on the step up therapy 
they received, only subjects in ICS+LABA had a statistically significant association 
between the adherence and ER visits. This is also in agreement with the existing 
literature, which documents better efficacy data for ICS+LABA combination than the 
ICS +LTRA.  
 
In the case of other health services utilization outcomes, contrary to the study 
hypothesis, hospital stay and use of SABs were not found to be significantly associated 
with the overall controller adherence levels as well the adherence levels to the individual 
add-on drug. Since the total number of hospitalizations in post index was low it might be 
possible that the study could not capture enough number of hospitalizations to establish a 
significant association.  
 
In case of SAB use, the controller adherence did not affect the utilization. As 
controller adherence is expected to be associated with improved control over asthma it 
was hypothesized that the improved control would lead to decreased symptoms and 
therefore decreased use of SAB. However the analysis did not show any significant 
association between controller adherence and SAB use. This can be explained by the 
possibility that a sub group of patients even though adherent to the controller medication 
may not be able to administer the controller drugs properly or likely to over treat the 
symptoms resulting in concurrent use of SABs. In a study done by Butz et al.
88
 found that 
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among pediatric asthma patients rate of SAB use actually went up with the use of 
controller drugs. They also postulated a possibility of sub groups of asthma patients 
having tendency to consume more drugs.  
 
 
5.3 Policy Implications  
 
This study could impact multiple interest groups namely insurance companies, 
managed care organizations, government agencies such as Medicaid/Medicare, Health 
care providers and asthma patients. 
 
Insurance companies/ Managed care designing pharmacy benefit plan: designing 
the pharmacy benefit plan in terms of various cost sharing levels is a challenging task for 
insurance companies and government agencies. Since the out of pocket cost plays an 
important role in the utilization of drugs
89
, defining the various cost sharing levels is 
crucial to optimize the drug utilization and improve adherence. From the health insurance 
companies‟ perspective, well-structured patient cost-sharing policies,90,91 have been 
shown to be more efficient in increasing the cost savings without adversely affecting the 
health outcomes.  
 
This study will provide helpful information in designing the patient cost sharing 
policies regarding the asthma controller drugs. The data such as price sensitivity of add-
on drugs will be helpful in determining the optimum cost sharing levels for the different 
add on therapies in a pharmacy benefit management policies. The benefits discussed 
above will apply to state Medicaid programs covering prescription drugs and also to 
Medicare because of the part D coverage now available to the Medicare beneficiaries.  
 
Patients‟ perspective: According to a 2002 national estimate, there are 20 million 
cases of asthma in the US
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 and this number is rising every year. Since asthma is a 
chronic condition with no cure available and treatment relying heavily on medication 
therapy, appropriate utilization of medication is imperative. Number of studies 
10, 
92
recently have demonstrated the reduced morbidity and improved asthma control being 
associated with the appropriate drug utilization. The current literature also documents 
considerable divergence
10
 from asthma guidelines in terms of controller drug utilization. 
This study will be helpful in explaining the role played by cost sharing levels in asthma 
patients‟ adherence to controller medication and different add-on options. The results 
from this study will be helpful in creating awareness amongst asthma patients about 
importance of controller medication for long term management of the asthma. It is 
expected that the policy changes based on the study results to be directed towards 
patient‟s interests to maximize the adherence to the controller treatment regimens.  
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Health care provider‟s perspective: The current literature provides convincing 
data on efficacy of both LABA and LTRA combinations through various clinical trials. 
However, there are a few controversies
87
 regarding the absolute dominance of one 
combination on other regarding the clinical outcomes. In terms of effectiveness of the 
combinations the data available from observational studies
93-95
 differ in their conclusions 
to establish a clear alternative.  Therefore in a situation where there is no apparent 
dominant strategy in terms of efficacy and effectiveness, this study will be useful in 
documenting information regarding the factors such as adherence of these options and 
their sensitivity to patient cost-sharing levels. The results from this study will be valuable 
to physicians and other health care providers in deciding the most appropriate add-on 
therapy that will improve the outcomes as well as adherence. The information such as 
knowing the combination therapies to which patients are more sensitive to cost can help 
understating the additional attention required in monitoring the adherence of the patients 
on those combinations.  
 
 
5.4 Future Research Directions 
 
For future studies more research should be done to generate more evidence 
establishing the cost sharing and adherence relationship. One possible way to improve 
this study would be to add more years of data so that the study subjects could be followed 
for a longer period of time this may produce more accurate estimates. Adding more years 
can also increase the sample size significantly allowing using more advanced techniques 
such as propensity score matching. Since there are new drugs introduced every year, the 
similar approach can be used by studying more recent data that can provide most recent 
drugs available in the market. Another limitation of this study was information on race 
and ethnicity was not available and therefore in future studies it would be interesting to 
collect information on race ethnicity that could be linked to the insurance claims data to 
get more accurate and unbiased estimates. The study also did not include data on income 
level and secondary insurance because of the limited information available in insurance 
claims database. To overcome these limitations, in future research, it would be of great 
importance to collect data on variables unavailable in insurance claims, such as race, 
ethnicity, income, secondary insurance. Combining this information with administrative 
claims data would create an ideal dataset to study more accurate and unbiased 
relationship.  
 
The study showed lower adherence levels both pre and post index period, 
therefore future studies should investigate the role played by adherence levels in 
increasing asthma severity levels that lead to stepped up therapy.  Currently the asthma 
treatment guidelines are based on the severity levels. If the severity levels are affected by 
the adherence then more attention needs to be focused in improving the adherence 
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because in such cases where patient is stepped up to dual controller therapy as result of 
lower adherence to prescribed drugs, stepping up may not be an appropriate choice.  
 
Finally, as the scope of this study was limited to patients with asthma only, this 
framework can be further extended to include more chronic conditions such as 
hypertension and diabetes where adherence to medication is very important in controlling 
the condition. Similar approaches in investigating those factors would be helpful in 
determining how price sensitive people are across a broad range of therapeutic groups 
which would ultimately help in designing most appropriate drug benefit plan. 
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